Search

Your search keyword '"Ewing, A."' showing total 5,019 results
Start Over Author "Ewing, A." Topic business
5,019 results on '"Ewing, A."'

1. Student Loans and Entrepreneurship: An Overview. Entrepreneurship Issue Brief. No. 5

Author

Ewing Marion Kauffman Foundation, Desai, Sameeksha, Looze, Jessica, and Pechenina, Anna

Abstract

Nearly 1 in 6 adults in the U.S. has outstanding student loan debt. Among those between the ages of 18 and 29, 1 in 3 reported having student loan debt. Meanwhile, the share of new entrepreneurs aged 20-34 declined from 34% to 27% between 1996 and 2019. The relationship between student loan debt and entrepreneurship sits at the intersection of many questions related to labor markets, higher education, business dynamism, innovation, and capital markets. This brief considers these intersections.

Published
2020

2. Young Entrepreneurs: Young People Dream of Becoming Entrepreneurs, despite America's Lingering Recession

Author

Ewing Marion Kauffman Foundation

Abstract

An August 2010 Harris Interactive[R] survey, commissioned by the Ewing Marion Kauffman Foundation, posed questions about entrepreneurship to 5,077 U.S. young people ages eight to twenty-four. The results show that business ownership continues to capture the imaginations of America's youth, particularly for those who know a successful entrepreneur personally. (Contains 20 resources.)

Published
2011

3. High-Growth Firms and the Future of the American Economy. Kauffman Foundation Research Series: Firm Formation and Economic Growth

Author

Ewing Marion Kauffman Foundation and Stangler, Dane

Abstract

Into early 2010, more than two years after the recession began, the American economy continues to send out mixed signals with respect to economic recovery: GDP (gross domestic product) growth looks set to recover, while unemployment is projected to remain high for many more years. The most important economic matter facing the country is job creation, not only in terms of employment itself but also for boosting sectors such as housing, which will not fully recover until job creation recovers. Discussions about jump-starting the U.S. economy--both from policymakers and pundits--primarily focus on measures that would expand job growth in existing companies. This report, the third in the Kauffman Foundation Research Series on Firm Formation and Economic Growth, draws on a new set of data, a special tabulation conducted by the Census Bureau at the request of the Ewing Marion Kauffman Foundation, calculated from the Business Dynamics Statistics (BDS) database. While previous research has emphasized the importance of new and young companies to job creation overall, this paper focuses on "high-growth firms"--the so-called "gazelles" that, despite their relatively small numbers, nonetheless account for a disproportionate share of job creation. The data generally show that: (1) In any given year, the top-performing 1 percent of firms generate roughly 40 percent of new job creation; and (2) Fast-growing young firms, comprising less than 1 percent of all companies, generate roughly 10 percent of new jobs in any given year. This paper examines the relevance of these points in the national discussion on job creation. When the current conversation turns to small business as an instigator in economic growth, it still emphasizes existing firms. But a new discussion--one that not only promotes entrepreneurship, but, specifically, "high-growth" entrepreneurship--is necessary, because top-performing companies are the most fruitful source of new jobs and offer the economy's best hope for recovery. Finally, this paper recommends strategies policymakers could follow to facilitate the creation and growth of more gazelle companies: (1) Remove barriers that potentially block the emergence of high-growth companies; (2) Focus on taxation, regulation, immigration, access to capital, and academic commercialization; and (3) Target immigrant entrepreneurs and universities, which may be likely sources for high-growth firms. (Contains 7 figures and 23 footnotes.)

Published
2010

4. Business Ethics. Digest Number 98-1.

Author

Ewing Marion Kauffman Foundation, Kansas City, MO. Center for Entrepreneurial Leadership. and Akhavan, Kambiz

Abstract

Discussion of business ethics rests on rather ambiguous grounds. What one person considers highly unethical can be legitimate in another person's eye. Many businesses operate under tenets that, although not illegal, most people would consider unethical. Having the ability to distinguish between ethical and unethical practices does not guarantee that a business owner will consistently choose the ethical decision. Business owners need to realize the tremendous benefits of operating an ethical company and severe disadvantages of using unethical operations. Guidelines that can help them create or improve the ethical standards within their companies include the following: (1) if the company has committed a serious error, do not attempt to cover it up; (2) create a believable public commitment to ethical operations; (3) establish a strategy to communicate the ethics guidelines to the staff; (4) build trust with employees and constantly monitor the ethics program; (5) hire people who can uphold the company's high ethical standards; and (5) realize that company executives are role models. Trust is one of the company's most vital assets. Maintaining the highest ethical standards adds to a company's value and success. Consequences of success in an unethical business are short lived. If customers or clients learn a company cheats, they may never return. A business cannot operate successfully if employees abuse sick days, cut corners on quality, lie to colleagues, cover up incidents, deceive customers, and take credit for co-workers' ideas. (YLB)

Published
1998

5. Artificial Intelligence's Imperfections Become Clearer: Efficiency and accuracy can emerge in an insurance sector powered by AI. What can happen when it's less than perfect?

Author

Ewing, Lance

Subjects
Artificial intelligence, Insurance industry, Artificial intelligence, Insurance industry, Business, Insurance
Abstract

In the days of the Wild West, a young cowboy was having difficulty filling out the beneficiary form for his deceased father. The insurance agent asked what the trouble was [...]

Published
2024

6. The Role of Dividend Policy in Explaining Corporate Governance and Profitability on Firm Value

Author

Yenny Dwi Handayani and Ewing Yuvisa Ibrani

Subjects
corporate governance, profitabilitas, dividend policy, firm value, indonesian banking, Business, HF5001-6182, Economics as a science, HB71-74
Abstract

This study aims to determine the effect of corporate governance and profitability on dividend policy based on substitution theory and/or outcome theory in the banking sector in Indonesia. Theoretically, this study contributes which theory is more dominant between substitution theory and outcome theory by linking the influence of corporate governance with dividend policy and providing information about the impact of the application of the theory on firm value and build awareness to be careful of investors. Investors in making investment decisions, especially in the banking industry in Indonesia. In addition, this study also examines the role of dividend policy in explaining the relationship between corporate governance and profitability on the value of banking firms. A sample of 135 observational data comes from 27 banking companies during 2016-2020. This research found that corporate governance has a negative and significant influence on dividend policy. In addition, the CG index is one of the factors that can explain the company's market value. Profitability is empirically proven to influence dividend policy. Dividend policy is proven to play a role in mediating the relationship between profitability and firm value. However, it is empirically proven that dividend policy cannot mediate the relationship between corporate governance and firm value.

Published
2023
Full Text
View/download PDF

7. Artificial intelligence focus and firm performance

Author

Mishra, Sagarika, Ewing, Michael T., and Cooper, Holly B.

Subjects
Artificial intelligence -- Usage, Marketing management -- Technology application, Artificial intelligence, Technology application, Advertising, marketing and public relations, Business
Abstract

Artificial Intelligence is poised to transform all facets of marketing. In this study, we examine the link between firms' focus on AI in their 10-K reports and their gross and net operating efficiency. 10-K reports are a salient source of insight into an array of issues in accounting and finance research, yet remain relatively overlooked in marketing. Drawing upon economic and marketing theory, we develop a guiding framework to show how firms' AI focus could be related to gross and net operating efficiency. We then use a system of simultaneous equations to empirically test the relationship between AI focus and operating efficiency. Our findings confirm that US-listed firms are in a state of impending transformation with regards to AI. We show how AI focus is associated with improvements in net profitability, net operating efficiency and return on marketing-related investment while reducing adspend and creating jobs., Author(s): Sagarika Mishra [sup.1] , Michael T. Ewing [sup.2] , Holly B. Cooper [sup.2] Author Affiliations: (1) grid.1021.2, 0000 0001 0526 7079, Department of Finance, Deakin University, , Burwood, Australia [...]

Published
2022
Full Text
View/download PDF

8. Following Ben Franklin's Adage About Protecting a Prime Asset: Life: In a world where employee life insurance might be a person's only coverage, why can't employers extend the benefit after a layoff?

Author

Ewing, Lance

Subjects
Layoffs, Life insurance, Employers, Employee benefits, Financial services industry, Financial services industry, Employee benefits, Layoff, Business, Insurance
Abstract

'Do you know the current value of your husband's policy?' the life insurance agent requested of the client. 'I am not sure what that means?' answered the woman. 'If you [...]

Published
2024

9. Minority Capital Resource Handbook. A Guide to Raising Capital for Minority Entrepreneurs. Second Edition.

Author

Security Industry Minority Capitol Foundation, Washington, DC., Ewing, Samuel D., and Maloney, Clifton H. W.

Abstract

This minority capital resource handbook consists of a guide to raising capital for minority entrepreneurs and a listing of sources that provide such capital. The first section deals with the process of raising capital. The realities of raising capital, intermediaries and financial advisors, and assessing needs are outlined. Factors considered in evaluating the entrepreneurial team and the venture are discussed. Six points to consider when presenting a proposal to an investor are examined, and a sample proposal is provided. The investigation and negotiation stages and post-financing relationships are also described. Individual investors and various institutions are discussed as potential sources of capital. The following types of institutions are covered: commercial banks, the small business administration, small business investment companies, venture capital firms, corporate venture capital activities, and minority enterprise small business investment companies (MESBICs). MESBICs in twenty-one states (California, Connecticut, Hawaii, Illinois, Kentucky, Louisiana, Maryland, Massachusetts, Mississippi, Michigan, New Jersey, New York, North Carolina, Ohio, Oklahoma, Pennsylvania, Texas, Virginia, Washington, West Virginia, and Wisconsin) are listed. A page of miscellaneous sources and a brief bibliography are provided. (MN)

Published
1980

10. Green is Good-The Impact of Information Nudges on the Selection of Voluntary Green-Power Plans

Author

Cardella, Eric, Ewing, Bradley T., and Williams, Ryan B.

Subjects
Consumer preferences -- Research -- Environmental aspects -- Surveys, Alternative energy sources -- Consumption data -- Economic aspects -- Surveys, Business, Economics, Petroleum, energy and mining industries
Abstract

A recent trend has been a move toward greater reliance on renewable or 'green' energy sources, especially in the residential sector. Using a choice experiment, this paper examines how providing information regarding the efficiency, cost, and environmental impacts of different power-generating sources impact consumers' stated preferences for selecting voluntary green-power plans. Based on 21,000 plan choices from two different samples totaling over 1,800 respondents, our results indicate that information nudges significantly impact respondents' choice of plan. Promoting the advantages of the green plan or the disadvantages of the 'gray' plan increase green plan selection. The magnitudes of these estimated effects are economically significant being roughly equivalent to a change in the monthly green price premium of $4/month. We also find that promoting the advantages of the green plan is more effective when the green plan premium is relatively small, while highlighting the drawbacks of the gray plan is more effective when the green plan premium is relatively large. Our results suggest that information nudges have the potential to be a plausible, economical, and effective mechanism to increase adoption of voluntary green-power plans. Keywords: Renewable energy, Green power, Information, Nudge, Choice experiment, 1. INTRODUCTION In the U.S., as well as in many other developed nations, there has been a growing trend toward greater reliance on renewable energy. One prominent area embodying this [...]

Published
2022
Full Text
View/download PDF

12. Reducing acid consumption: Maximizing sulfuric acid alkylation unit profitability

Author

Peterson, J. R., Rana, D., and Ewing, R.

Subjects
Gasoline -- Production processes, Alkylation -- Methods, Petroleum -- Refining, Sulfuric acid -- Usage, Business, Petroleum, energy and mining industries
Abstract

Alkylation is a process used to produce highly branched isoparaffins from the reaction of lighter olefins and isobutane in the presence of sulfuric acid as a catalyst. This highly branched [...]

Published
2021

13. Public Health Responses to Pandemics in 1918 and 2020

Author

E. Thomas Ewing

Subjects
2019-20 coronavirus outbreak, medicine.medical_specialty, Coronavirus disease 2019 (COVID-19), business.industry, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Public health, Public Health, Environmental and Occupational Health, COVID-19, Global Health, Environmental health, Pandemic, Global health, medicine, Humans, Public Health, business, Pandemics
Published
2023

14. Getting the Right Golf Insurance Coverage Isn't Always Par for the Course: Hitting the links may not always be the most relaxing exercise for everyone. Keep your head up and watch out for liability traps on the links

Author

Ewing, Lance

Subjects
Golfers -- Insurance, Golf courses -- Insurance, Business, Insurance
Abstract

After hitting his second consecutive tee shot into the pond, the angry golfer grabbed his bag from the caddie and walked to the edge of the water. He tossed his [...]

Published
2023

16. Randomized controlled trial of motivational interviewing for alcohol and cannabis use within a predominantly Hispanic adolescent sample

Author

Travis I. Lovejoy, Genevieve F. Dash, Brian Borsari, Sarah W. Feldstein Ewing, Angela D. Bryan, and Sarah J. Schmiege

Subjects
Adolescent, Alcohol Drinking, media_common.quotation_subject, Ethnic group, Psychological intervention, Motivational interviewing, PsycINFO, Motivational Interviewing, Underage Drinking, Article, law.invention, Randomized controlled trial, law, Intervention (counseling), Medicine, Humans, Pharmacology (medical), media_common, Cannabis, Pharmacology, Cannabinoid Receptor Agonists, biology, Ethanol, business.industry, Addiction, Hispanic or Latino, biology.organism_classification, Psychiatry and Mental health, Hallucinogens, business, Clinical psychology
Abstract

Hispanic youth represent one of the fastest-growing minority groups. Yet, we know little about Hispanic adolescents' response to empirically-supported interventions for adolescent addiction, including motivational interviewing (MI). This randomized controlled trial (RCT) compared MI to an active educational treatment for adolescent alcohol and cannabis use (alcohol and cannabis education; ACE). Adolescents who regularly use substances (N = 448; n = 347 Hispanic; n = 101 non-Hispanic white; ages 13-18) were randomized to two 1-hr individual sessions of MI or ACE. We examined 6-month outcomes and mechanisms of change across Hispanic and non-Hispanic white youth. Treatment response was comparable across ethnicities (Hispanic vs. non-Hispanic white youth). Additionally, adolescents in the MI condition showed greater reductions in alcohol use compared to those in ACE, with support for motivation and self-efficacy as mechanisms of treatment response. Direct effects of MI on cannabis use were not observed; however, a significant indirect effect of motivation was observed for reductions in cannabis use. Data support the efficacy of MI in reducing adolescent alcohol use, through the vehicle of enhanced motivation and self-efficacy. While consistent treatment response was observed for adolescent alcohol use across ethnicities (Hispanic vs. non-Hispanic white), further exploration into potential underexplored mechanisms of Hispanic adolescents' treatment response is requisite to strengthening prevention and intervention programming for Hispanic adolescents' cannabis use. (PsycInfo Database Record (c) 2021 APA, all rights reserved).

Published
2023

17. Math Heroes for Young Readers: Young, mathematically minded readers will find inspiration in this collection of picture-book biographies, which covers the lives of history's most influential mathematicians

Author

Young, Terrell A. and Monroe, Eula Ewing

Subjects
Picture books, Biographies, Readers (People), Books, Childhood, Mathematicians, Heroes, Business, Publishing industry
Abstract

Role models are important for everyone, especially children, who need to be inspired, motivated, and encouraged to believe in their own potential. Oftentimes role models enter our lives in person, [...]

Published
2019

19. Determinant of non-GAAP earnings management practices and its impact on firm value

Author

Ewing Yuvisa Ibrani, Faisal Faisal, and Yenny Dwi Handayani

Subjects
non-gaap earnings management, fraud diamond, pressure, opportunity, rationalization, capability, Business, HF5001-6182, Management. Industrial management, HD28-70
Abstract

This study aims to examine the factors that explain the reasons why non-GAAP earnings management is carried out based on the fraud diamond theory (FDT). FDT is a theory widely used in behavioral research to explain the factors that cause fraud in a company. In addition, this study also explains the impact of non-GAAP earnings management practices on firm value. This study investigates 42 non-bank and financial companies listed on Indonesia Stock Exchange (IDX) for the period 2010–2017. The results of the logistic regression analysis founded that opportunity and ability were the most dominant factors causing non-GAAP earnings management. The findings of this study show that in Indonesia, there is need for greater attention from the regulators to the opportunity and capability factors to reduce the occurrence of non-GAAP earnings management.

Published
2019
Full Text
View/download PDF

20. IRS issues tax inflation adjustments for tax year 2022

Author

Fischer, Myles B. and Ewing, Brendan H.

Subjects
United States. Internal Revenue Service -- Powers and duties, Transfer taxes -- Economic aspects -- Laws, regulations and rules, Tax policy -- Evaluation, Estates (Law) -- Management -- Taxation, Government regulation, Company business management, Business, Business, regional
Abstract

Byline: Special to the RBJ The Internal Revenue Service recently issued Revenue Procedure 2021-45 providing calendar year 2022 inflation adjustments for more than60 tax provisions.Two of these adjustments are of [...]

Published
2021

22. Energy Recommendations for Michigan's Upper Peninsula Heading to Governor

Author

Ewing, Tom

Subjects
Task forces, Propane -- Prices and rates, Company pricing policy, Business, Petroleum, energy and mining industries
Abstract

After months of speculation, Michigan's Department of Environment, Great Lakes and Energy (EGLE) posted the UP Energy Task Force's draft recommendations for Line 5, the 30-inch (762-mm), light crude and [...]

Published
2020

23. Children undergoing outpatient complex penile surgery and hypospadias repair may not require opioid analgesics

Author

Laura B. Cornwell, Kelly Swords, Paul C Campbell, and Emily Ewing

Subjects
Male, medicine.medical_specialty, 03 medical and health sciences, 0302 clinical medicine, Urethra, 030225 pediatrics, Outpatients, medicine, Humans, Penile surgery, Child, Hypospadias, Pain, Postoperative, Degloving, business.industry, Infant, Multimodal therapy, General Medicine, Perioperative, medicine.disease, Surgery, Analgesics, Opioid, Catheter, Opioid, Child, Preschool, 030220 oncology & carcinogenesis, Pediatrics, Perinatology and Child Health, Number needed to treat, business, Penis, medicine.drug
Abstract

Pain control is important after penile surgery, and opioid use should be minimized as able. We sought to describe our experience performing complex penile surgeries with vs without post-operative opioids.A retrospective review of penile surgeries, including 3998 between 2009 and 2019. We identified patients8 years who underwent outpatient penile surgery requiring either penile degloving or hypospadias repair. Patients who were or were not prescribed opioids were matched 1:1 by age and type of penile surgery. Primary outcomes of interest were pain-related encounters, delayed opioid prescription, and predictors of pain.200 children were identified, 100 per group, with mean age 1.3 ± 0.8 years. 48% were penile degloving procedures, 31% hypospadias repairs with catheters, and the remaining 21% hypospadias repairs without catheters. Perioperative features were comparable between groups(p 0.05). 59% of patients without opioids had an impromptu post-operative encounter vs 41%, and 20% had an associated pain complaint vs 9%(p = 0.026). Two patients in both groups received delayed opioid prescription(p = 1.00). The presence of a catheter (OR 2.9) and no opioid prescription (OR 2.6) were independent predictors for pain complaint.Patients discharged without an opioid were more likely to contact a provider postoperatively and were more likely to endorse pain complaint (number needed to treat: 9).

Published
2022

24. Safety, immunogenicity, and efficacy of a COVID-19 vaccine (NVX-CoV2373) co-administered with seasonal influenza vaccines: an exploratory substudy of a randomised, observer-blinded, placebo-controlled, phase 3 trial

Author

Seth Toback, Eva Galiza, Catherine Cosgrove, James Galloway, Anna L Goodman, Pauline A Swift, Sankarasubramanian Rajaram, Alison Graves-Jones, Jonathan Edelman, Fiona Burns, Angela M Minassian, Iksung Cho, Lakshmi Kumar, Joyce S Plested, E Joy Rivers, Andreana Robertson, Filip Dubovsky, Greg Glenn, Paul T Heath, Roy L. Soiza, Robin Brittain-Long, Chiara Scicluna, Carole Edwards, Lynn Mackay, Mariella D'Allesandro, Amy Nicol, Karen Norris, Sandra Mann, Heather Lawrence, Ruth Valentine, Marianne Elizabeth Viljoen, Carol H. Pretswell, Helen Nicholls, Imrozia Munsoor, Agnieszka Meyrick, Christina Kyriakidou, Shalini Iyengar, Arham Jamal, Nick Richards, Helen Price, Bridie Rowbotham, Danielle Bird, Karen Smith, Olga Littler, Kirsty Fielding, Anna Townsend-Rose, Karen Miller, Jessica Davis, Alison Elliot-Garwood, Lauren Trottier, Paul Edwards, Margaret McFarland, Orod Osanlou, Laura Longshaw, Jane Stockport, Lynne Grundy, Katharine Lucy Broad, Karen Regan, Kim Storton, Declan Ryan-Wakeling, Brad Wilson, Malathy Munisamy, John Wright, Anil Shenoy, Beverley English, Lucy Brear, Paola Cicconi, Marta Boffito, Ana Milinkovic, Ruth Byrne, Roya Movahedi, Rosalie Housman, Naveed Kara, Ellen Brown, Andrea Cipriani, Mary-Jane Attenburrow, Katharine A. Smith, Jonathan Packham, Geoff Sparrow, Richard Smith, Josephine M. Rosier, Khalid Saja, Nyasha Nago, Brian Camilleri, Anita Immanuel, Mike Hamblin, Rawlings Osagie, Mahalakshmi Mohan, Hilary Floyd, Suzanne Goddard, Sanjay Mutgi, John Evans, Sean McKeon, Neringa Vilimiene, Rosavic Chicano, Rachel Hayre, Alice Pandaan, Catherine Henshall, Sonia Serrano, Andrea Mazzella, Thurkka Rajeswaran, Moncy Mathew, Karen Bisnauthsing, Laura Bremner, Henry Fok, Franca Morselli, Paola Cinardo, Blair Merrick, Lucy Sowole, Samantha Broadhead, Natalie Palmer, Jessica Cordle, Jaimie Wilson Goldsmith, Enya Cooney, Beth Jackson, Thilina Jayatilleke, Zelda Cheng, Toby Helliwell, Adrian Chudyk, Rafaela Giemza, John Lord Villajin, Noah Yogo, Esther Makanju, Pearl Dulawan, Deepak Nagra, April Buazon, Alice Russell, Georgie Bird, Amardeep Heer, Rex Sarmiento, Balraj Sanghera, Melanie Mullin, Adam Champion, Aisling Bevan, Kinzah Iqbal, Alshia Johnson, Rebecca Clark, Sarah Shaw, Steven Shaw, Amanda Chalk, Martin Lovatt, Caroline Lillicrap, Angela Parker, Jan Hansel, Zhi Wong, Galvin Gan, Eyad Tuma, Jane Minton, Jennifer Murira, Razan Saman, Alistair Hall, Kyra Holliday, Zara Khan, James Calderwood, George Twigg, Helena Baker, Julie Corrigan, Katy Houseman, Subhra Raguvanshi, Dominic Heining, Jake Weddell, Liz Glaves, Kim Thompson, Francis Davies, Ruth Lambley Burke, Emma C. Thomson, Dinesh Saralaya, Lisa Berry, Nancy Hopewell, Leigh Gerdes, Mihaela Pacurar, Saul N. Faust, Jeremy Turner, Christopher Jeanes, Adele Cooper, Jocelyn Keshet-Price, Lou Coke, Melissa Cambell-Kelly, Ketan Dhatariya, Claire Williams, Georgina Marks, James Sudbury, Lisa Rodolico, Judy Bradley, Sharon Carr, Roisin Martin, Angelina Madden, Paul Biagioni, Sonia McKenna, Alison Clinton, Maurice O'Kane, Justin Carter, Matthew Dewhurst, Bill Wetherill, Thandiwe Hoggarth, Katrina Lennon Collins, Marie Chowdhury, Adil Nathoo, Anna Heinen, Orla MacDonald, Claudia Hurducas, Liliana Cifuentes, Harjeevan Gill, Andy Gibson, Raha West, Jane Ewing, Rachel Blacow, John Haughney, Jonathan MacDonald, John Paul Seenan, Stewart Webb, Colin O'Leary, Scott Muir, Beth White, Neil Ritchie, Daniel F. McAuley, Jonathan Stewart, Mariella D'Alessandro, Nicki Lakeman, Laura Purandare, Duncan Browne, David Tucker, Peter Luck, Angharad Everden, Lisa Trembath, Michael Visick, Nick Morley, Laura Reid, Helen Chenoweth, Kirsty Maclean, Ray P. Sheridan, Tom Burden, Craig Francis Lunt, Shirley Todd, Stephanie Estcourt, Jasmine Marie Pearce, Suzanne Wilkins, Cathryn Love-Rouse, Eva Torok-Pollok, Mike Youle, Sara Madge, Danielle Solomon, Aarti Nandani, Janet M. North, Nargis Hemat, Rachel Newport, Philip A. Kalra, Chukwuma Chukwu, Olivia Wickens, Vikki O'Loughlin, Hema Mistry, Louise Harrison, Robert Oliver, Anne-Marie Peers, Jess Zadik, Katie Doyle, David R. Chadwick, Kerry Colling, Caroline Wroe, Marie Branch, Alison Chilvers, Sarah Essex, Mark Stone, Alberto San Francisco Ramos, Emily Beales, Olivia Bird, Zsofia Danos, Hazel Fofie, Cecilia Hultin, Sabina Ikram, Fran Mabesa, Aoife Mescall, Josyanne Pereira, Jennifer Pearce, Natalina Sutton, Emma Snashall, David Neil Baxter, Sara Bennett, Debbie Suggitt, Kerry Hughes, Wiesia Woodyatt, Lynsey Beacon, Alissa Kent, Chris Cooper, Milan Rudic, Simon Tunstall, Matthew Jackson, Claire Hombersley, Patrick Moore, Rebecca Cutts, Andrew Higham, Marwan Bukhari, Mohamed Elnaggar, Michelle Glover, Fiona Richardson, Alexandra Dent, Shahzeb Mirza, Rajiv Ark, Jennie Han, Suzy V. Hope, Philip J. Mitchelmore, Rostam Osanlou, Andrew Freedman, Alison Cooper, Katherine Burton, Kashyap Katechia, Michael Barrett, Jo Salkeld, Natalie Hill, Nathaniel Lee, Jon Perkins, and Polly Fox

Subjects
Adult, Pulmonary and Respiratory Medicine, Trivalent influenza vaccine, medicine.medical_specialty, COVID-19 Vaccines, Adolescent, Influenza vaccine, Population, Placebo, Young Adult, Immunogenicity, Vaccine, Double-Blind Method, Internal medicine, Humans, Medicine, education, Adverse effect, Aged, education.field_of_study, Reactogenicity, SARS-CoV-2, business.industry, COVID-19, Articles, Middle Aged, Vaccine efficacy, Vaccination, Influenza Vaccines, Seasons, business
Abstract

Background The safety and immunogenicity profile of COVID-19 vaccines when administered concomitantly with seasonal influenza vaccines have not yet been reported. We therefore aimed to report the results of a substudy within a phase 3 UK trial, by evaluating the safety, immunogenicity, and efficacy of NVX-CoV2373 when co-administered with licensed seasonal influenza vaccines. Methods We did a planned exploratory substudy as part of the randomised, observer-blinded, placebo-controlled, phase 3 trial of the safety and efficacy of the COVID-19 vaccine (NVX-CoV2373) by co-administrating the influenza vaccine at four study hospitals in the UK. Approximately, the first 400 participants meeting the main study entry criteria—with no contraindications to influenza vaccination—were invited to join the substudy. Participants of the main study were randomly assigned (1:1) to receive two intramuscular injections of either NVX-CoV2373 (5 μg) or placebo (normal saline) 21 days apart; participants enrolled into the substudy were co-vaccinated with a single (0·5 mL) intramuscular, age-appropriate (quadrivalent influenza cell-based vaccine [Flucelvax Quadrivalent; Seqirus UK, Maidenhead] for those aged 18–64 years and adjuvanted trivalent influenza vaccine [Fluad; Seqirus UK, Maidenhead] for those ≥65 years), licensed, influenza vaccine on the opposite deltoid to that of the first study vaccine dose or placebo. The influenza vaccine was administered in an open-label manner and at the same time as the first study injection. Reactogenicity was evaluated via an electronic diary for 7 days after vaccination in addition to monitoring for unsolicited adverse events, medically attended adverse events, and serious adverse events. Immunogenicity was assessed with influenza haemagglutination inhibition and SARS-CoV-2 anti-spike protein IgG assays. Vaccine efficacy against PCR-confirmed, symptomatic COVID-19 was assessed in participants who were seronegative at baseline, received both doses of study vaccine or placebo, had no major protocol deviations affecting the primary endpoint, and had no confirmed cases of symptomatic COVID-19 from the first dose until 6 days after the second dose (per-protocol efficacy population). Immunogenicity was assessed in participants who received scheduled two doses of study vaccine, had a baseline sample and at least one post-vaccination sample, and had no major protocol violations before unmasking (per-protocol immunogenicity population). Reactogenicity was analysed in all participants who received at least one dose of NVX-CoV2373 or placebo and had data collected for reactogenicity events. Safety was analysed in all participants who received at least one dose of NVX-CoV2373 or placebo. Comparisons were made between participants of the substudy and the main study (who were not co-vaccinated for influenza). This study is registered with ClinicalTrials.gov, number NCT04583995. Findings Between Sept 28, 2020, and Nov 28, 2020, a total of 15 187 participants were randomised into the main phase 3 trial, of whom 15 139 received treatment (7569 received dose one of NVX-CoV2373 and 7570 received dose one of placebo). 431 participants were co-vaccinated with a seasonal influenza vaccine in the substudy (217 received NVX-CoV2373 plus the influenza vaccine and 214 received placebo plus the influenza vaccine). In general, the substudy participants were younger, more racially diverse, and had fewer comorbid conditions than those in the main study. Reactogenicity events were more common in the co-administration group than in the NVX-CoV2373 alone group: tenderness (113 [64·9%] of 174 vs 592 [53·3%] of 1111) or pain (69 [39·7%] vs 325 [29·3%]) at injection site, fatigue (48 [27·7%] vs 215 [19·4%]), and muscle pain (49 [28·3%] vs 237 [21·4%]). Incidences of unsolicited adverse events, treatment-related medically attended adverse events, and serious adverse events were low and balanced between the co-administration group and the NVX-CoV2373 alone group. No episodes of anaphylaxis or deaths were reported within the substudy. Co-administration resulted in no change to influenza vaccine immune response although a reduction in antibody responses to the NVX-CoV2373 vaccine was noted. NVX-CoV2373 vaccine efficacy in the substudy (ie, participants aged 18 to

Published
2022

25. Novel Oppositional Defiant Disorder 6 Months After Traumatic Brain Injury in Children and Adolescents

Author

Jeffrey E. Max, Russell Schachar, John R. Hesselink, Florin Vaida, Daniel S Lowet, Tony T. Yang, Harvey S. Levin, Elisabeth A. Wilde, Sandra B. Chapman, Linda Ewing-Cobbs, Anish Kolan, Ann E. Saunders, Hattan Arif, Olga Tymofiyeva, and Erin D. Bigler

Subjects
Biopsychosocial model, Adolescent, Traumatic brain injury, business.industry, Not Otherwise Specified, medicine.disease, Magnetic Resonance Imaging, Psychiatry and Mental health, Psychiatric history, Social Class, Attention Deficit and Disruptive Behavior Disorders, Conduct disorder, Brain Injuries, Child, Preschool, Oppositional defiant, Brain Injuries, Traumatic, medicine, Humans, Neurology (clinical), Child, business, Psychosocial, Socioeconomic status, Clinical psychology
Abstract

Objective The investigators aimed to assess predictive factors of novel oppositional defiant disorder (ODD) among children and adolescents in the first 6 months following traumatic brain injury (TBI). Methods Children ages 5-14 years who experienced a TBI were recruited from consecutive admissions to five hospitals. Testing of a biopsychosocial model that may elucidate the development of novel ODD included assessment soon after injury (baseline) of preinjury characteristics, including psychiatric disorders, adaptive function, family function, psychosocial adversity, family psychiatric history, socioeconomic status, injury severity, and postinjury processing speed (which may be a proxy for brain injury). MRI analyses were also conducted to examine potential brain lesions. Psychiatric outcome, including that of novel ODD, was assessed 6 months after the injury. Results A total of 177 children and adolescents were recruited for the study, and 134 who were without preinjury ODD, conduct disorder, or disruptive behavior disorder not otherwise specified (DBD NOS) returned for the 6-month assessment. Of those who returned 6 months postinjury, 11 (8.2%) developed novel ODD, and none developed novel conduct disorder or DBD NOS. Novel ODD was significantly associated with socioeconomic status, preinjury family functioning, psychosocial adversity, and processing speed. Conclusions These findings show that an important minority of children with TBI developed ODD. Psychosocial and injury-related variables, including socioeconomic status, lower family function, psychosocial adversity, and processing speed, significantly increase risk for this outcome.

Published
2022

26. CDC LOCATe: discrepancies between self-reported level of maternal care and LOCATe-assessed level of maternal care among 463 birth facilities

Author

Jennifer L. Beauregard, M. Kathryn Menard, Alexander C. Ewing, Sabrina A. Madni, David A. Goodman, and Mary D. Brantley

Subjects
medicine.medical_specialty, business.industry, Family medicine, Pediatrics, Perinatology and Child Health, Obstetrics and Gynecology, Medicine, Obstetric ultrasound, business, Healthcare system
Abstract

OBJECTIVE Describe sources of discrepancy between self-assessed LoMC (level of maternal care) and CDC LOCATe®-assessed (Levels of Care Assessment Tool) LoMC. STUDY DESIGN CDC LOCATe® was implemented at 480 facilities in 13 jurisdictions, including states, territories, perinatal regions, and hospital systems, in the U.S. Cross-sectional analyses were conducted to compare facilities' self-reported LoMC and LOCATe®-assessed LoMC. RESULT Among 418 facilities that self-reported an LoMC, 41.4% self-reported a higher LoMC than their LOCATe®-assessed LoMC. Among facilities with discrepancies, the most common elements lacking to meet self-reported LoMC included availability of maternal-fetal medicine (27.7%), obstetric-specializing anesthesiologist (16.2%), and obstetric ultrasound services (12.1%). CONCLUSION Two in five facilities self-report a LoMC higher than their LOCATe®-assessed LoMC, indicating discrepancies between perceived maternal care capabilities and those recommended in current LoMC guidelines. Results highlight an opportunity for states to engage with facilities, health systems, and other stakeholders about LoMC and collaborate to strengthen systems for improving maternal care delivery.

Published
2021

27. Hypertension at delivery hospitalization – United States, 2016–2017

Author

Carla L. DeSisto, Cheryl L. Robbins, Jean Y. Ko, Alexander C. Ewing, Elena V. Kuklina, and Matthew D. Ritchey

Subjects
Adult, medicine.medical_specialty, Pregnancy, Databases, Factual, Pregnancy Associated Hypertension, business.industry, Obstetrics and Gynecology, Hypertension, Pregnancy-Induced, Delivery, Obstetric, medicine.disease, United States, Hospitalization, Hypertension, Emergency medicine, Prevalence, Internal Medicine, Hospital discharge, medicine, Humans, Female, Chronic hypertension, business, Healthcare Cost and Utilization Project, Retrospective Studies
Abstract

In this study, hospital discharge data from the 2016–2017 Healthcare Cost and Utilization Project were analyzed to describe national and, where data were available, state-specific prevalences of chronic hypertension and pregnancy-associated hypertension at delivery hospitalization. In 2016–2017, the prevalence of chronic hypertension was 216 per 10,000 delivery hospitalizations nationwide, ranging from 125 to 400 per 10,000 delivery hospitalizations in individual states. The prevalence of pregnancy-associated hypertension was 1021 per 10,000 delivery hospitalizations nationwide, ranging from 693 to 1382 per 10,000 delivery hospitalizations in individual states. The burden of hypertensive disorders in pregnancy remains high and varies considerably by jurisdiction.

Published
2021

28. Thyroid-optimized and thyroid-sparing radiotherapy in oral cavity and oropharyngeal carcinoma: A dosimetric study

Author

Wesley Zoller, V.M. Diavolitsis, Ghazal Khandel, Eric D. Miller, M.Z. Kharouta, Jennifer A. Sipos, Dukagjin Blakaj, John C. Grecula, Jacob Eckstein, Ashlee Ewing, E. Healy, Jessica Wobb, Mauricio E. Gamez, Sachin R. Jhawar, Aashish D. Bhatt, Anna K. Wu, Stella Ling, N. Damico, Alok Deshane, and D.L. Mitchell

Subjects
medicine.medical_specialty, endocrine system, endocrine system diseases, Intensity-modulated radiotherapy, medicine.medical_treatment, R895-920, Oral cavity, Radiation toxicity, Medical physics. Medical radiology. Nuclear medicine, Hypothyroidism, medicine, Thyroid-sparing, Radiology, Nuclear Medicine and imaging, In patient, Head and neck, Care Planning, Thyroid-optimized, RC254-282, integumentary system, Oncology (nursing), business.industry, Health Policy, Thyroid, Cancer, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, medicine.disease, Radiation therapy, medicine.anatomical_structure, Oropharyngeal Carcinoma, Toxicity, Radiology, business, therapeutics, Research Article
Abstract

Highlights • This feasibility study showed thyroid sparing in head and neck cancer patients. • Thyroid sparing with acceptable target volume coverage was possible with IMRT. • Average mean dose to thyroid was significantly reduced with thyroid optimization. • Thyroid optimized plans had relatively unchanged doses to surrounding OARs., Background Radiation-induced hypothyroidism is a common toxicity of head and neck radiation. Our re-planning study aimed to reduce thyroid dose while maintaining target coverage with IMRT. Methods We retrospectively identified patients with oral-cavity (n = 5) and oropharyngeal cancer (n = 5). Treatment plans were re-optimized with 45 Gy thyroid mean dose constraint, then we cropped the thyroid out of PTVs and further reduced thyroid dose. Target coverage was delivering 100% dose to ≥ 93% of PTV and 95% of dose to > 99% of PTV. Results Originally, average mean dose to thyroid was 5580 cGy. In model I, this dropped to 4325 cGy (p

Published
2021

29. Modeling the Response of Gasoline-Crude Oil Price Crack Spread Macroeconomic Shocks

Author

Ewing, Bradley T. and Thompson, Mark A.

Subjects
Macroeconomics -- Forecasts and trends, Gasoline -- Forecasts and trends -- Prices and rates, Monetary policy, Financial risk -- Management, Autoregression (Statistics) -- Analysis, Corporate debt -- Forecasts and trends, Petroleum -- Prices and rates -- Forecasts and trends, Company business management, Market trend/market analysis, Company pricing policy, Business, general, Business
Abstract

Abstract To date, considerable attention has been given to evaluating movements in crude oil and gasoline prices and in determining the significance of fundamental state variables that may influence these [...]

Published
2018
Full Text
View/download PDF

30. Impact of Hospital Strain on Excess Deaths During the COVID-19 Pandemic — United States, July 2020–July 2021

Author

Moira Johnson, Marc Dion, Kaitlyn Webster, Maria Ewing, Josh Corman, Geoffrey French, Mary Hulse, Katharine Sobotka, Brago Aboagye-Nyame, Benjamin Zalinger, and Debbie Nguyen

Subjects
Adult, medicine.medical_specialty, Health (social science), Epidemiology, Health, Toxicology and Mutagenesis, Staffing, Prevalence, Psychological intervention, law.invention, Health Information Management, law, Environmental health, Health care, Pandemic, Humans, Medicine, Full Report, Mortality, Pandemics, Bed Occupancy, business.industry, Public health, COVID-19, General Medicine, Emergency department, Intensive care unit, Hospitals, United States, Intensive Care Units, business
Abstract

Surges in COVID-19 cases have stressed hospital systems, negatively affected health care and public health infrastructures, and degraded national critical functions (1,2). Resource limitations, such as available hospital space, staffing, and supplies led some facilities to adopt crisis standards of care, the most extreme operating condition for hospitals, in which the focus of medical decision-making shifted from achieving the best outcomes for individual patients to addressing the immediate care needs of larger groups of patients (3). When hospitals deviated from conventional standards of care, many preventive and elective procedures were suspended, leading to the progression of serious conditions among some persons who would have benefitted from earlier diagnosis and intervention (4). During March-May 2020, U.S. emergency department visits declined by 23% for heart attacks, 20% for strokes, and 10% for diabetic emergencies (5). The Cybersecurity & Infrastructure Security Agency (CISA) COVID Task Force* examined the relationship between hospital strain and excess deaths during July 4, 2020-July 10, 2021, to assess the impact of COVID-19 surges on hospital system operations and potential effects on other critical infrastructure sectors and national critical functions. The study period included the months during which the highly transmissible SARS-CoV-2 B.1.617.2 (Delta) variant became predominant in the United States.† The negative binomial regression model used to calculate estimated deaths predicted that, if intensive care unit (ICU) bed use nationwide reached 75% capacity an estimated 12,000 additional excess deaths would occur nationally over the next 2 weeks. As hospitals exceed 100% ICU bed capacity, 80,000 excess deaths would be expected in the following 2 weeks. This analysis indicates the importance of controlling case growth and subsequent hospitalizations before severe strain. State, local, tribal, and territorial leaders could evaluate ways to reduce strain on public health and health care infrastructures, including implementing interventions to reduce overall disease prevalence such as vaccination and other prevention strategies, as well as ways to expand or enhance capacity during times of high disease prevalence.

Published
2021

31. Spectral Considerations for Standoff Infrared Detection of RDX on Reflective Aluminum

Author

Kevin J. Major, Mikella E. Farrell, Ellen L. Holthoff, Paul M. Pellegrino, Jasbinder S. Sanghera, and Kenneth J. Ewing

Subjects
Materials science, Optics, Explosive material, chemistry, Infrared, Aluminium, business.industry, chemistry.chemical_element, Specular reflection, Diffuse reflection, business, Instrumentation, Spectroscopy
Abstract

This paper examines infrared spectroscopic effects for the standoff detection of an explosive material, hexahydro-1,3,5-trinitro-1,3,5-triazine (RDX), inkjet printed on an aluminum surface. Results of a spectroscopic study are described, using multiple optical setups. These setups were selected to explore how variations in the angles of incidence and collection from the surface of the material result in corresponding variations in the spectral signatures. The goal of these studies is to provide an understanding of these spectral changes since it affects standoff detection of hazardous materials on a reflective substrate. We demonstrate that variations in spectral effects are dependent on the relative surface concentration of the deposited RDX. We also show that it is reasonable to use spectroscopic data collected in a standard laboratory infrared spectrometer outfitted with a variable angle reflectometer set at 0° as reference spectra for data collected in a standoff configuration. These results are important to provide a systematic approach to understanding infrared (IR) spectra collection using standoff systems in the field, and to allow for comparison between such data, and data collected in the laboratory. Although the precise results are constrained to a specific material system (thin layers on a reflective substrate), the approach and general discussion provided are applicable to a broad range of IR standoff sensing techniques and applications.

Published
2021

32. Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2+ breast cancer in the adaptively randomized I-SPY2 trial

Author

Denise M. Wolf, Jane Perlmutter, Judy C. Boughey, A. Jo Chien, Meredith Buxton, Gillian L. Hirst, Douglas Yee, Angela DeMichele, Andres Forero-Torres, Scott M. Berry, Erin D. Ellis, Anthony D. Elias, Julia Wulfkuhle, Michael Alvarado, Christina Yau, Stacy L. Moulder, Nola M. Hylton, Rita Nanda, Amy Wilson, Adam Asare, Debu Tripathy, Claudine Isaacs, Melissa Paoloni, Rosa I. Gallagher, Laura J. Esserman, Richard Schwab, W. Fraser Symmans, Cheryl Ewing, Laura J. van't Veer, Jeffrey B. Matthews, Teresa Helsten, Julia L. Clennell, Barbara Haley, Emanuel F. Petricoin, Katherine Steeg, Smita Asare, Ashish Sanil, Rachel L. Yung, Erin P. Crane, Erin Roesch, Hyo S. Han, Ruby Singhrao, Michelle E. Melisko, Hope S. Rugo, Kathy S. Albain, Donald A. Berry, Anne M. Wallace, Julie E. Lang, Amy S. Clark, Kathleen Kemmer, and Lamorna Brown-Swigart

Subjects
Oncology, Receptor, ErbB-2, General Physics and Astronomy, Ado-Trastuzumab Emtansine, chemistry.chemical_compound, Breast cancer, ErbB-2, Trastuzumab, Monoclonal, skin and connective tissue diseases, Humanized, Cancer, Multidisciplinary, Tumor, medicine.diagnostic_test, Middle Aged, Neoadjuvant Therapy, Paclitaxel, 6.1 Pharmaceuticals, Pertuzumab, medicine.drug, Receptor, Adult, medicine.medical_specialty, Cyclophosphamide, Science, Clinical Trials and Supportive Activities, Context (language use), Breast Neoplasms, Antibodies, Monoclonal, Humanized, Article, General Biochemistry, Genetics and Molecular Biology, Antibodies, Clinical Research, Internal medicine, Biopsy, Breast Cancer, Biomarkers, Tumor, medicine, Humans, Doxorubicin, Maytansine, neoplasms, Aged, business.industry, Evaluation of treatments and therapeutic interventions, General Chemistry, Translational research, medicine.disease, chemistry, business, Biomarkers
Abstract

HER2-targeted therapy dramatically improves outcomes in early breast cancer. Here we report the results of two HER2-targeted combinations in the neoadjuvant I-SPY2 phase 2 adaptive platform trial for early breast cancer at high risk of recurrence: ado-trastuzumab emtansine plus pertuzumab (T-DM1/P) and paclitaxel, trastuzumab and pertuzumab (THP). Eligible women have >2.5 cm clinical stage II/III HER2+ breast cancer, adaptively randomized to T-DM1/P, THP, or a common control arm of paclitaxel/trastuzumab (TH), followed by doxorubicin/cyclophosphamide, then surgery. Both T-DM1/P and THP arms ‘graduate’ in all subtypes: predicted pCR rates are 63%, 72% and 33% for T-DM1/P (n = 52), THP (n = 45) and TH (n = 31) respectively. Toxicity burden is similar between arms. Degree of HER2 pathway signaling and phosphorylation in pretreatment biopsy specimens are associated with response to both T-DM1/P and THP and can further identify highly responsive HER2+ tumors to HER2-directed therapy. This may help identify patients who can safely de-escalate cytotoxic chemotherapy without compromising excellent outcome., HER2-targeted therapy improves patient’s outcome in early breast cancer. Here, the authors present the efficacy and biomarker analysis of two HER2-targeted combinations (ado-trastuzumab emtansine plus pertuzumab and paclitaxel, trastuzumab and pertuzumab) in the context of the neoadjuvant I-SPY2 phase 2 adaptive platform trial for early breast cancer at high risk of recurrence.

Published
2021

33. Randomized Community Trial Comparing Telephone versus Clinic‐Based Behavioral Health Counseling for People Living with HIV in a Rural Setting

Author

Wendy Ewing, Lisa A. Eaton, Harold P. Katner, Marnie Hill, Moira O. Kalichman, and Seth C. Kalichman

Subjects
Counseling, Rural Population, medicine.medical_specialty, business.industry, Rural health, Nutrition Education, Medical record, Public Health, Environmental and Occupational Health, HIV Infections, Telehealth, Medication Adherence, Telephone, Discontinuation, Telephone counseling, Pill, Family medicine, Intervention (counseling), medicine, Humans, business
Abstract

Purpose To test the efficacy of a theory-based behavioral intervention delivered via telephone versus clinic-based counseling to improve HIV outcomes and reduce alcohol consumption for people at-risk for treatment failure in a rural setting. Methods Patients receiving HIV care (N = 240) were randomized using a computer-generated scheme to one of three conditions: (a) telephone behavioral health counseling, (b) clinic-based behavioral health counseling, or (c) attention control nutrition education. Behavioral counseling was delivered by either a community nurse or a paraprofessional patient navigator, with differences examined. Participants were followed for 12 months to assess medication adherence using unannounced pill counts and alcohol use measured by electronic daily text message assessments, and 18 months for HIV viral load and retention in care extracted from medical records. Findings There was evidence for telephone and office-based counseling demonstrating greater medication adherence than the control condition but only in the short term. Clinic-based behavioral counseling significantly reduced alcohol use to a greater degree than telephone counseling and the control condition. There were no other differences between conditions. There were also no discernable differences between counseling delivered by the community nurse and the patient navigator. Conclusions Telephone and clinic-based counseling demonstrated improved medication adherence in the short term, while clinic-based counseling demonstrated reductions in alcohol use. The modest outcomes suggest that intensive intervention strategies are needed for patients that clinicians identify as at-risk for treatment discontinuation and treatment failure.

Published
2021

34. The B‐APNEIC score: distilling the STOP‐Bang questionnaire to identify patients at high risk for severe obstructive sleep apnoea

Author

Ruben J. Azocar, Sadeq A. Quraishi, S. Ewing, R. Morinigo, and R. Schumann

Subjects
Adult, Male, Neck circumference, Pediatrics, medicine.medical_specialty, Polysomnography, Logistic regression, Risk Factors, Surveys and Questionnaires, medicine, Humans, Stop bang, Prospective Studies, Aged, Sleep Apnea, Obstructive, medicine.diagnostic_test, Receiver operating characteristic, business.industry, Patient Acuity, Middle Aged, Sleep in non-human animals, respiratory tract diseases, Anesthesiology and Pain Medicine, Blood pressure, Female, business, Body mass index
Abstract

The STOP-Bang questionnaire is an established clinical screening tool to identify the risk of having mild, moderate or severe obstructive sleep apnoea using eight variables. It is unclear whether all eight variables contribute equally to the risk of clinically significant obstructive sleep apnoea. We analysed each variable for its contribution to detecting obstructive sleep apnoea; based on the results, we investigated whether the STOP-Bang questionnaire could be abbreviated to identify patients at high risk for severe obstructive sleep apnoea. We recruited patients with suspected obstructive sleep apnoea who were referred for overnight polysomnography. We used multivariable logistic regression to investigate the association of STOP-Bang parameters with severe obstructive sleep apnoea based on clinical and polysomnography data. Regression estimates were used to select variables to create the novel B-APNEIC score. We constructed receiver operating characteristic curves for the STOP-Bang questionnaire and B-APNEIC scores to identify patients with severe obstructive sleep apnoea and compared the areas under the curve using the DeLong method. Of the 275 patients enrolled, 32% (n = 88) had severe obstructive sleep apnoea. Logistic regression demonstrated that neck circumference (OR 2.20; 95%CI 1.10-4.40, p = 0.03) was the only variable independently associated with severe obstructive sleep apnoea. Observed apnoea during sleep, blood pressure and body mass index were the three next most closely trending predictors of severe obstructive sleep apnoea and were included along with neck circumference in the B-APNEIC score. Receiver operating curves demonstrated that the areas under the curve for STOP-Bang vs. B-APNEIC were comparable for identifying patients with severe obstructive sleep apnoea (OR 0.75; 95%CI 0.68-0.81 vs. OR 0.75; 95%CI 0.68-0.81: p = 0.99, respectively). Our results suggest that the B-APNEIC score is a simplified adaptation of the STOP-Bang questionnaire with equivalent effectiveness in identifying patients with severe obstructive sleep apnoea. Further studies are needed to validate and build on our findings.

Published
2021

35. 'I'm fine!': Assertions of lack of support need among patients with chronic obstructive pulmonary disease: A mixed-methods study

Author

Efthalia Massou, Morag Farquhar, A Carole Gardener, Gail Ewing, Robbie Duschinsky, Caroline Moore, Gardener, A Carole [0000-0002-8064-3780], and Apollo - University of Cambridge Repository

Subjects
medicine.medical_specialty, Chronic Obstructive Pulmonary Disease, Pulmonary disease, compliance, 03 medical and health sciences, Pulmonary Disease, Chronic Obstructive, 0302 clinical medicine, medicine, Humans, 030212 general & internal medicine, Longitudinal Studies, Stage (cooking), Intensive care medicine, disavowal, COPD, 030504 nursing, business.industry, Health Policy, help-seeking, Palliative Care, General Medicine, Focus Groups, medicine.disease, Help-seeking, Self Report, support needs, 0305 other medical science, business
Abstract

Funder: Marie Curie; FundRef: https://doi.org/10.13039/501100000654, OBJECTIVES: To understand how people with Chronic Obstructive Pulmonary Disease (COPD) disavow their support needs and the impact on care. METHODS: Two stage mixed-method design. Stage 1 involved sub-analyses of data from a mixed-method population-based longitudinal study exploring the needs of patients with advanced COPD. Using adapted criteria from mental health research, we identified 21 patients who disavowed their needs from the 235 patient cohort. Qualitative interview transcripts and self-report measures were analysed to compare these patients with the remaining cohort. In stage 2 focus groups (n = 2) with primary healthcare practitioners (n = 9) explored the implications of Stage 1 findings. RESULTS: Patients who disavowed their support needs described non-compliance with symptom management and avoidance of future care planning (qualitative data). Analysis of self-report measures of mental and physical health found this group reported fewer needs than the remaining sample yet wanted more GP contact. The link between risk factors and healthcare professional involvement present in the rest of the sample was missing for these patients. Focus group data suggested practitioners found these patients challenging. DISCUSSION: This study identified patients with COPD who disavow their support needs, but who also desire more GP contact. GPs report finding these patients challenging to engage.

Published
2022

37. Twelve-Month Outcomes of the AFFINITY Trial of Fluoxetine for Functional Recovery After Acute Stroke: AFFINITY Trial Steering Committee on Behalf of the AFFINITY Trial Collaboration

Author

Graeme J. Hankey, Maree L. Hackett, Osvaldo P. Almeida, Leon Flicker, Gillian E. Mead, Martin S. Dennis, Christopher Etherton-Beer, Andrew H. Ford, Laurent Billot, Stephen Jan, Thomas Lung, Erik Lundström, Katharina S. Sunnerhagen, Craig S. Anderson, Huy Thang-Nguyen, John Gommans, Qilong Yi, Veronica Murray, Robert Herbert, Gregory Carter, Geoffrey A. Donnan, Huy-Thang Nguyen, Qiang Li, Severine Bompoint, Sarah Barrett, Anne Claxton, Julia O’Dea, Michelle Tang, Clare Williams, Shenae Peterson, Christie Drummond, Uyen-Ha Hong, Linh-Thi My Le, Tram-Thi Bich Ngo, Yen-Bao Mai, Huyen-Thanh Han, Nhu-Quynh Truong, Huong-Thi Nguyen, Hai-Thanh Ngo, Thi Binh Nguyen, Oanh-Thi Kieu Ha, Trang-Le Huyen Nguyen, Richard I. Lindley, Peter New, Andrew Lee, Thanh-Trung Tran, Loan-Tran Truc Mai Le, Thuy-Le Vu Kieu, Sang-Van Nguyen, Thuy-Anh Diem Nguyen, Tam-Nhat Dang, Hanh-Thi Truc Phan, Loan-Thi Ngoc Vo, Mai-Hue Nguyen, Hanh-Cao Dang, Hong-Thi Tran, Linh-Thi Cam Dam, Trinh-Thi Kim Ngo, Thai-Nguyen Thanh Pham, Binh-Nguyen Pham, Nha-Thi Thanh Dao, Huong-Thi Bich Nguyen, Linh-Thi Cam Le, Chi-Minh Do, Huy-Quoc Huynh, Giau-Thi Kim Tran, Oanh-Thi Le, Ly-Thi Khanh Tran, Chinh-Dinh Duong, Duong-Van Kieu, Na Le, Hoa-Ngoc Nguyen, Binh-Van Le, Long-Thanh Nguyen, Long-Van Nguyen, Tuan-Quoc Dinh, Tan-Van Vo, Tram-Ngoc Bui, Uyen-Thi To Hoang, Hien-Thi Bich Nguyen, Ha-Thi Thu Nguyen, Nga-Thuy Lam, Khanh-Kim Le, Phuong-Thanh Trinh, Hop-Quang Huynh, Thao-Thi Thu Nguyen, Huyen-Ngoc Lu, Tham-Hong Pham, Sam-Hoanh Nguyen, Ninh-Hong Le, Giang-Truong Nguyen, Bich-Thi Doan, Sung-Phuoc Pham, Duong-Huu Luong, Ha-Van Mai, Thuc-Van Tran, Phuong-Thi Do, Hoai-Thi Le, Chi-Van Nguyen, Phuong-Doan Nguyen, Ton-Duy Mai, Phuong-Viet Dao, Dung-Tien Nguyen, Dai-Quoc Khuong, Trung-Xuan Vuong, Lan-Tuong Vu, Ngoc-Duc Ngo, Hanh-Hong Dang, Phuong-Thai Truong, Ngan-Thi Le, Hoa-Van Hoang, Chung-Quang Do, Minh-Thao Nguyen, Anh-Hai Dam, Quynh-Nhu Le, Ngoc-Hoang Nguyen, Tuyen-Van Nguyen, Toan-Dinh Le, Ha-Thi Hai Dinh, Cuong–Van Pham, Khanh-Thi Ngoc Thach, Linh-Hai Nguyen, Loan-Thi Nguyen, Vien-Chi Le, Phuong-Hong Tran, Tai-Anh Nguyen, Tuan-Van Le, Luyen-Van Truong, Tue-Chau Bui, Ngoc-Xuan Huynh, Lap-Van Dinh, An-Gia Pham, Trang-Thi Huyen Le, Vy-Tuong Nguyen, Yen-Hai Nguyen, Thang-Ba Nguyen, Huy Thai, Quyen-Thi Ngoc Pham, Khoa-Duy Dao, Quoc-Nguyen Bao Pham, Thuong-Thi Huyen Dang, Huong-Huynh To Dinh, Trang-Mai Tong, Thuy-Thi Vu, Si-Tri Le, Tai-Ngoc Tran, Phuong-Hoai Tran, Ngoc-Thuy Nhu Dinh, Binh-Thanh Nguyen, Vinh-Phuong Do, Anh-Ngoc Nguyen, Binh-Thi Thanh Nguyen, David Blacker, Lindsey Bunce, Ai Ling Tan, Darshan Ghia, Gillian Edmonds, Nicole O’Loughlin, Megan Ewing, Kerri-Ann Whittaker, Lorralee Deane, Yash Gawarikar, Brett Jones, Maria Lopez, Koushik Nagesh, Emma Siracusa, Stephen Davis, Amy McDonald, Jess Tsoleridis, Rachael McCoy, David Jackson, Gab Silver, Timothy R. Bates, Amanda Boudville, Lynda Southwell, Dennis Cordato, Alan J. McDougall, Cecilia Cappelen-Smith, Zeljka Calic, Shabeel Askar, Qi Cheng, Raymond Kumar, Richard Geraghty, Maree Duroux, Megan Ratcliffe, Samantha Shone, Cassandra McLennan, Ramesh Sahathevan, Casey Hair, Stanley Levy, Beverley Macdonald, Benjamin Nham, Louise Rigney, Dev Nathani, Sumana Gopinath, Vishal Patel, Abul Mamun, Benjamin Trewin, Chun Phua, Ho Choong, Lauren Tarrant, Kerry Boyle, Luisa Hewitt, Monique Hourn, Amanda Masterson, Kim Oakley, Karen Ruddell, Colette Sanctuary, Kimberley Veitch, Camelia Burdusel, Lina Lee, Gary Cheuk, Jeremy Christley, Tabitha Hartwell, Craig Davenport, Kate Hickey, Rosanna Robertson, Michelle Carr, Sam Akbari, Hannah Coyle, Megan O’Neill, Cameron Redpath, Caroline Roberts, Marjan Tabesh, Toni Withiel, Kapila Abeysuriya, Andrew Granger, Angela Abraham, Chermaine Chua, Dung Do Nguyen, Vathani Surendran, Melissa Daines, David Shivlal, Mudassar Latif, Noreen Mughal, Patricia Morgan, Martin Krause, Miriam Priglinger, Ehsan E. Shandiz, Susan Day, Lay Kho, Michael Pollack, Judith Dunne, Helen Baines, Merridie Rees, Jenni White, Aicuratiya Withanage, Candice Delcourt, Cheryl Carcel, Alejandra Malavera, Amy Kunchok, Elizabeth Ray, Elizabeth Pepper, Emily Duckett, Sally Ormond, Andrew Moey, Timothy Kleinig, Vanessa Maxwell, Chantal Baldwin, Wilson Vallat, Deborah Field, Romesh Markus, Kirsty Page, Danielle Wheelwright, Sam Bolitho, Steven Faux, Fix Sangvatanakul, Alexis Brown, Susan Walker, Jennifer Massey, Hillary Hayes, Pesi Katrak, Annie Winker, Alessandro Zagami, Alanah Bailey, Sarah Mccormack, Andrew Murray, Mark Rollason, Christopher Taylor, Fintan O’Rourke, Ye Min Kuang, Heike Burnet, Yvonne Liu, Aileen Wu, Diana Ramirez, Tissa Wijeratne, Sherisse Celestino, Essie Low, Cynthia Chen, Jennifer Bergqvist, Andrew Evans, Queenie Leung, Martin Jude, Rachael McQueen, Katherine Mohr, Latitia Kernaghan, Paul Stockle, Boon L. Tan, Sara Laubscher, Diana Schmid, Melissa Spooner, Bhavesh Lallu, Bronwen Pepperell, John Chalissery, Karim Mahawish, Susan DeCaigney, Paula Broughton, Karen Knight, Veronica Duque, Harry McNaughton, Jeremy Lanford, Vivian Fu, and Lai-Kin Wong

Subjects
Male, medicine.medical_specialty, Steering committee, medicine.medical_treatment, Placebo, B700, Fractures, Bone, Cognition, Double-Blind Method, Recurrence, Seizures, Fluoxetine, Internal medicine, Humans, Medicine, Stroke, Fatigue, Aged, Ischemic Stroke, Acute stroke, Advanced and Specialized Nursing, business.industry, Recovery of Function, Middle Aged, Functional recovery, medicine.disease, Clinical trial, Affect, Hemorrhagic Stroke, Quality of Life, Accidental Falls, Female, Neurology (clinical), Cardiology and Cardiovascular Medicine, business, Stroke recovery, Selective Serotonin Reuptake Inhibitors, medicine.drug
Abstract

Background and Purpose: The AFFINITY trial (Assessment of Fluoxetine in Stroke Recovery) reported that oral fluoxetine 20 mg daily for 6 months after acute stroke did not improve functional outcome and increased the risk of falls, bone fractures, and seizures. After trial medication was ceased at 6 months, survivors were followed to 12 months post-randomization. This preplanned secondary analysis aimed to determine any sustained or delayed effects of fluoxetine at 12 months post-randomization. Methods: AFFINITY was a randomized, parallel-group, double-blind, placebo-controlled trial in adults (n=1280) with a clinical diagnosis of stroke in the previous 2 to 15 days and persisting neurological deficit who were recruited at 43 hospital stroke units in Australia (n=29), New Zealand (4), and Vietnam (10) between 2013 and 2019. Participants were randomized to oral fluoxetine 20 mg once daily (n=642) or matching placebo (n=638) for 6 months and followed until 12 months after randomization. The primary outcome was function, measured by the modified Rankin Scale, at 6 months. Secondary outcomes for these analyses included measures of the modified Rankin Scale, mood, cognition, overall health status, fatigue, health-related quality of life, and safety at 12 months. Results: Adherence to trial medication was for a mean 167 (SD 48) days and similar between randomized groups. At 12 months, the distribution of modified Rankin Scale categories was similar in the fluoxetine and placebo groups (adjusted common odds ratio, 0.93 [95% CI, 0.76–1.14]; P =0.46). Compared with placebo, patients allocated fluoxetine had fewer recurrent ischemic strokes (14 [2.18%] versus 29 [4.55%]; P =0.02), and no longer had significantly more falls (27 [4.21%] versus 15 [2.35%]; P =0.08), bone fractures (23 [3.58%] versus 11 [1.72%]; P =0.05), or seizures (11 [1.71%] versus 8 [1.25%]; P =0.64) at 12 months. Conclusions: Fluoxetine 20 mg daily for 6 months after acute stroke had no delayed or sustained effect on functional outcome, falls, bone fractures, or seizures at 12 months poststroke. The lower rate of recurrent ischemic stroke in the fluoxetine group is most likely a chance finding. Registration: URL: http://www.anzctr.org.au/ ; Unique identifier: ACTRN12611000774921.

Published
2021

38. FSH Level and Changes in Bone Mass and Body Composition in Older Women and Men

Author

Vilmundur Guðnason, Ann V. Schwartz, Trisha F. Hue, Sigurður Sigurðsson, Clifford J. Rosen, Annegreet G Veldhuis-Vlug, Xiaojuan Li, Anne L. Schafer, Mone Zaidi, Thomas Lang, Gina N Woods, Deborah M. Kado, Susan K. Ewing, Karin C. Wu, Tiffany Y. Kim, and Eric Vittinghoff

Subjects
Male, 0301 basic medicine, medicine.medical_specialty, Endocrinology, Diabetes and Metabolism, Clinical Biochemistry, 030209 endocrinology & metabolism, Context (language use), Biochemistry, Bone remodeling, 03 medical and health sciences, Absorptiometry, Photon, 0302 clinical medicine, Endocrinology, Bone Density, Internal medicine, medicine, Humans, Quantitative computed tomography, Testosterone, Femoral neck, Aged, 80 and over, Bone mineral, Clinical Research Article, medicine.diagnostic_test, Femur Neck, business.industry, Biochemistry (medical), Bone Diseases, Metabolic, 030104 developmental biology, medicine.anatomical_structure, Adipose Tissue, Cohort, Body Composition, Female, Composition (visual arts), Follicle Stimulating Hormone, business
Abstract

Context FSH may have independent actions on bone remodeling and body fat regulation. Cross-sectionally, we have shown that serum FSH is associated with bone mineral density (BMD) and body fat in older postmenopausal women, but it remains unknown whether FSH predicts bone and fat changes. Objective We examined whether baseline FSH level is associated with subsequent bone loss or body composition changes in older adults. Setting, Design, Participants We studied 162 women and 158 men (mean age 82 ± 4 years) from the Age, Gene/Environment Susceptibility (AGES)-Bone Marrow Adiposity cohort, a substudy of the AGES-Reykjavik Study of community-dwelling older adults. Skeletal health and body composition were characterized at baseline and 3 years later. Main Outcomes Annualized change in BMD and body composition by dual-energy X-ray absorptiometry (DXA) and quantitative computed tomography (QCT). Models were adjusted for serum estradiol and testosterone levels. Results There was no evidence for an association between baseline FSH level and change in BMD or body composition by DXA or QCT. For femoral neck areal BMD, adjusted mean difference (95% CI) per SD increase in FSH was 1.3 (-0.7 to 3.3) mg/cm2/y in women, and -0.2 (-2.6 to 2.2) mg/cm2/y in men. For visceral fat, adjusted mean difference (95% CI) per SD increase in FSH was 1.80 (-0.03 to 3.62) cm2/y in women, and -0.33 (-3.73 to 3.06) cm2/y in men. Conclusions Although cross-sectional studies and studies in perimenopausal women have demonstrated associations between FSH and BMD and body composition, in older adults, FSH level is not associated with bone mass or body composition changes.

Published
2021

39. SARS-CoV-2 seropositivity and subsequent infection risk in healthy young adults: a prospective cohort study

Author

Daniel Stadlbauer, Hua Wei Chen, Peifang Sun, Ernesto Santa Ana, Russell P. Tracy, Stuart C. Sealfon, Sagie Mofsowitz, Dawn L. Weir, Megan A. Schilling, Venugopalan D. Nair, Florian Krammer, Jan Marayag, William D. Graham, Yongchao Ge, Rhonda A. Lizewski, Daniel Ewing, Edgar Nunez, Mary Catherine George, Alexander Bukreyev, Andrew G. Letizia, Preeti Bharaj, Natalia Kuzmina, Nada Marjanovic, Chad K. Porter, Franca R. Jones, Sindhu Vangeti, Alessandra Soares-Schanoski, Clare M. Miller, Irene Ramos, Michael Termini, Carl Goforth, Corey A. Balinsky, Danielle M. Parent, Stephen E. Lizewski, and Victor A. Sugiharto

Subjects
Pulmonary and Respiratory Medicine, medicine.medical_specialty, Rate ratio, law.invention, Serology, 03 medical and health sciences, 0302 clinical medicine, law, Internal medicine, Quarantine, medicine, Humans, Medical history, 030212 general & internal medicine, Young adult, Prospective cohort study, SARS-CoV-2, business.industry, COVID-19, Articles, Virus Shedding, 030228 respiratory system, Reinfection, business, Risk assessment, Cohort study
Abstract

Background Whether young adults who are infected with SARS-CoV-2 are at risk of subsequent infection is uncertain. We investigated the risk of subsequent SARS-CoV-2 infection among young adults seropositive for a previous infection. Methods This analysis was performed as part of the prospective COVID-19 Health Action Response for Marines study (CHARM). CHARM included predominantly male US Marine recruits, aged 18–20 years, following a 2-week unsupervised quarantine at home. After the home quarantine period, upon arrival at a Marine-supervised 2-week quarantine facility (college campus or hotel), participants were enrolled and were assessed for baseline SARS-CoV-2 IgG seropositivity, defined as a dilution of 1:150 or more on receptor-binding domain and full-length spike protein ELISA. Participants also completed a questionnaire consisting of demographic information, risk factors, reporting of 14 specific COVID-19-related symptoms or any other unspecified symptom, and brief medical history. SARS-CoV-2 infection was assessed by PCR at weeks 0, 1, and 2 of quarantine and participants completed a follow-up questionnaire, which included questions about the same COVID-19-related symptoms since the last study visit. Participants were excluded at this stage if they had a positive PCR test during quarantine. Participants who had three negative swab PCR results during quarantine and a baseline serum serology test at the beginning of the supervised quarantine that identified them as seronegative or seropositive for SARS-CoV-2 then went on to basic training at Marine Corps Recruit Depot—Parris Island. Three PCR tests were done at weeks 2, 4, and 6 in both seropositive and seronegative groups, along with the follow-up symptom questionnaire and baseline neutralising antibody titres on all subsequently infected seropositive and selected seropositive uninfected participants (prospective study period). Findings Between May 11, 2020, and Nov 2, 2020, we enrolled 3249 participants, of whom 3168 (98%) continued into the 2-week quarantine period. 3076 (95%) participants, 2825 (92%) of whom were men, were then followed up during the prospective study period after quarantine for 6 weeks. Among 189 seropositive participants, 19 (10%) had at least one positive PCR test for SARS-CoV-2 during the 6-week follow-up (1·1 cases per person-year). In contrast, 1079 (48%) of 2247 seronegative participants tested positive (6·2 cases per person-year). The incidence rate ratio was 0·18 (95% CI 0·11–0·28; p

Published
2021

41. A Survey of Multimodal Sensor Fusion for Passive RF and EO Information Integration

Author

Robert L. Ewing, Peter Zulch, Jenny Liu, Erik Blasch, Asad Vakil, and Jia Li

Subjects
Artificial neural network, Computer science, business.industry, Machine vision, Digital imaging, Aerospace Engineering, Sensor fusion, Space and Planetary Science, Feature (computer vision), Histogram, Computer vision, Radio frequency, Artificial intelligence, Electrical and Electronic Engineering, business, Information integration
Abstract

Integrating information collected by different types of sensors observing the same or related phenomenon can lead to more accurate and robust decision making. The purpose of this article is to review sensor fusion approaches to achieve passive radio frequency (RF) and electro-optical (EO) sensor fusion and to present the proposed fusion of EO/RF neural network (FERNN). While research has been conducted to integrate complementary data collected by EO and RF modalities, the processing of RF data usually applies traditional features, such as Doppler. This article explores the viability of using the histogram of I/Q (in-phase and quadrature) data for the purposes of augmenting the detection accuracy that EO input alone is incapable of achieving. Specifically, by processing the histogram of I/Q data via deep learning and enhancing feature input for neural network fusion. Using the simulated data from the Digital Imaging and Remote Sensing Image Generation dataset, FERNN can achieve 95% accuracy in vehicle detection and scenario categorization, which is a 23% improvement over the accuracy achieved by a stand-alone EO sensor.

Published
2021

42. A Single-Center Retrospective Review of Perioperative Complications and Reoperation Rates Between Open Cranial Vault Remodeling and Distraction Osteogenesis for Unilateral Coronal Craniosynostosis

Author

Rachel M Segal, George N. Kamel, Alvin Wong, Emily Ewing, Michael Hornacek, Samuel Lance, Amanda A. Gosman, and Mary Kristine Carbulido

Subjects
Reoperation, medicine.medical_specialty, medicine.medical_treatment, Osteogenesis, Distraction, Single Center, Craniosynostosis, Craniosynostoses, Cranial vault, medicine, Humans, Retrospective Studies, Retrospective review, business.industry, Skull, Infant, General Medicine, Perioperative, Unilateral coronal craniosynostosis, medicine.disease, Surgery, Treatment Outcome, Otorhinolaryngology, Cohort, Distraction osteogenesis, business
Abstract

Background Unilateral coronal craniosynostosis (UCS) is the third most prevalent form of craniosynostosis. Traditional treatment of UCS has been achieved with fronto-orbital advancement and cranial vault remodeling (FOAR), but utilization of cranial distraction osteogenesis (DO) techniques has increased. This study aims to compare perioperative complications and reoperation trends in FOAR versus DO techniques at a single institution. Methods An Institutional Review Board-approved retrospective review was performed from January 1999 to November 2018 at a single institution. Patients were those that have undergone FOAR or DO with an anterior rotational flap technique as previously described. Indications for secondary procedures included: contour deformities, relapse, surgical site infection, and persistent cranial defects. Results Eighty-one patients with UCS were identified, 64 patients underwent FOAR and 17 patients underwent DO. When perioperative characteristics were compared, patients who underwent DO were younger in age, however, there was no significant difference in transfusion requirement or length of stay between patient cohorts. Surgery time was increased in DO patients. When perioperative complications were compared, more intraoperative dural tears were observed in the FOAR cohort. When unplanned reoperation rates were compared, patients who had undergone FOAR had a statistically significant higher reoperation rates at 5 years of follow up. When including routine distractor removal as a reoperation, reoperative rate was increased in the DO cohort. No difference in reoperation rates was noted at 5 years following index operation. Conclusions The safety profile of DO is similar to that of traditional FOAR techniques for treatment of UCS. Longer-term follow-up studies are needed to elucidate whether outcomes are durable, but the unplanned reoperation rate in DO is less than that of FOAR at 5 years and presents several advantages that warrants its use in patients with UCS.

Published
2021

43. Floating on a Chemical Sea

Author

Samuel Dylan Ewing

Subjects
Cultural Studies, Color film, Engineering, Visual Arts and Performing Arts, business.industry, Computer graphics (images), Launched, business
Abstract

When the Polaroid Corporation launched the now-iconic SX-70 system in 1972, it represented a series of technological breakthroughs. The color film developed automatically, and the collapsible camer...

Published
2021

44. Texas Implements New Pipeline Safety Regulations

Author

Ewing, Tom

Subjects
ATMOS Energy Corp. -- Safety and security measures -- Laws, regulations and rules, Pipelines -- Laws, regulations and rules, Gas transmission industry -- Laws, regulations and rules, Legislative bills -- Laws, regulations and rules, Gas utilities -- Laws, regulations and rules, Safety regulations, Natural gas -- Laws, regulations and rules, Public utilities, Government regulation, Business, Construction and materials industries, Petroleum, energy and mining industries
Abstract

Texas' natural gas utilities need to be ready for two new state pipeline safety programs: filing incident reports within one-hour of an accident, and removing underground cast-iron pipe by Dec. [...]

Published
2019

45. Open data from the first and second observing runs of advanced LIGO and advanced Virgo

Author

Rich&nbsp, Abbott, Thomas&nbsp, Sheelu&nbsp, Abraham, Fausto&nbsp, Acernese, Kendall&nbsp, Ackley, Carl&nbsp, Adams, Rana&nbsp, Adhikari, Vaishali&nbsp, Adya, Christoph&nbsp, Affeldt, Michalis&nbsp, Agathos, Kazuhiro&nbsp, Agatsuma, Nancy&nbsp, Aggarwal, Odylio&nbsp, Aguiar, Amit&nbsp, Aich, Lorenzo&nbsp, Aiello, Anirban&nbsp, Ain, Ajith&nbsp, Parameswaran, Gabrielle&nbsp, Allen, Annalisa&nbsp, Allocca, Paul&nbsp, Altin, Alex&nbsp, Amato, Shreya&nbsp, Anand, Alena&nbsp, Ananyeva, Stuart&nbsp, Anderson, Warren&nbsp, Svetoslava, Angelova, Stefano&nbsp, Ansoldi, Sarah&nbsp, Antier, Stephen&nbsp, Appert, Koji&nbsp, Arai, Melody, Araya, Joseph, Areeda, Marc&nbsp, Arène, Nicolas&nbsp, Arnaud, Scott, Aronson, Arun, Kg, Ascenzi, Gregory&nbsp, Ashton, Stuart, Aston, Pia&nbsp, Astone, Florian&nbsp, Aubin, Peter&nbsp, Aufmuth, Kellie&nbsp, Aultoneal, Corey&nbsp, Austin, Valerie&nbsp, Avendano, Stanislav&nbsp, Babak, Philippe&nbsp, Bacon, Francesca&nbsp, Badaracco, Maria, Bader, Sangwook&nbsp, Bae, Anne, Baer, Jonathon&nbsp, Baird, Baldaccini, Giulio&nbsp, Ballardin, Stefan, Ballmer, Anna-marie&nbsp, Bals, Alexander&nbsp, Balsamo, Baltus, Sharan&nbsp, Banagiri, Deepak&nbsp, Bankar, Rameshwar, Bankar, Juan, Barayoga, Claudio&nbsp, Barbieri, Barry, Barish, David&nbsp, Barker, Kevin&nbsp, Barkett, Pablo&nbsp, Barneo, Fabrizio&nbsp, Barone, Bryan&nbsp, Barr, Lisa&nbsp, Barsotti, Matteo&nbsp, Barsuglia, Daniel&nbsp, Barta, Jeffrey&nbsp, Bartlett, Imre&nbsp, Bartos, Riccardo&nbsp, Bassiri, Andrea&nbsp, Basti, Mateusz&nbsp, Bawaj, Joseph, Bayley, Marco&nbsp, Bazzan, Bence&nbsp, Bécsy, Michal&nbsp, Bejger, Imene&nbsp, Belahcene, Angus, Bell, Deeksha&nbsp, Beniwal, Michael, Benjamin, Joe, Bentley, Fabio&nbsp, Bergamin, Beverly, Berger, Gerald&nbsp, Bergmann, Sebastiano&nbsp, Bernuzzi, Christopher, Berry, Diego&nbsp, Bersanetti, Alessandro&nbsp, Bertolini, Joseph&nbsp, Betzwieser, Rohan&nbsp, Bhandare, Ankit, Bhandari, Bidler, Edward&nbsp, Biggs, Igor, Bilenko, Garilynn&nbsp, Billingsley, Ross&nbsp, Birney, Ofek&nbsp, Birnholtz, Sebastien&nbsp, Biscans, Bischi, Sylvia&nbsp, Biscoveanu, Aparna&nbsp, Bisht, Guldauren&nbsp, Bissenbayeva, Massimiliano&nbsp, Bitossi, Marieanne, Bizouard, Kent, Blackburn, Jonathan&nbsp, Blackman, Carl, Blair, David, Blair, Ryan, Blair, Bobba, Nina&nbsp, Bode, Michel&nbsp, Boer, Yannick&nbsp, Boetzel, Gilles&nbsp, Bogaert, Francois&nbsp, Bondu, Edgard&nbsp, Bonilla, Romain&nbsp, Bonnand, Phillip&nbsp, Booker, Boris, Boom, Rolf&nbsp, Bork, Valerio&nbsp, Boschi, Sukanta&nbsp, Bose, Vladimir&nbsp, Bossilkov, Joel&nbsp, Bosveld, Yann&nbsp, Bouffanais, Antonella&nbsp, Bozzi, Carlo&nbsp, Bradaschia, Patrick, Brady, Alyssa&nbsp, Bramley, Marica&nbsp, Branchesi, Jim, Brau, Breschi, Tristan&nbsp, Briant, Joseph, Briggs, Francesco&nbsp, Brighenti, Alain&nbsp, Brillet, Brinkmann, Patrick&nbsp, Brockill, Aidan, Brooks, Brooks, Daniel, Brown, Sharon&nbsp, Brunett, Giacomo&nbsp, Bruno, Robert&nbsp, Bruntz, Aaron&nbsp, Buikema, Tomasz&nbsp, Bulik, Henk, Bulten, Alessandra&nbsp, Buonanno, Damir&nbsp, Buskulic, Robert, Byer, Miriam&nbsp, Cabero, Laura&nbsp, Cadonati, Giampietro&nbsp, Cagnoli, Craig&nbsp, Cahillane, Juan&nbsp, Calderón&nbsp, Bustillo, Jack, Callaghan, Thomas, Callister, Enrico&nbsp, Calloni, Jordan, Camp, Maurizio&nbsp, Canepa, Kipp, Cannon, Huy-tuong&nbsp, Cao, Junwei&nbsp, Giovanni&nbsp, Carapella, Franco&nbsp, Carbognani, Santiago&nbsp, Caride, Matthew, Carney, Gregorio&nbsp, Carullo, Julia&nbsp, Casanueva&nbsp, Diaz, Claudio&nbsp, Casentini, Javier&nbsp, Castañeda, Sarah&nbsp, Caudill, Marco&nbsp, Cavaglià, Fabien&nbsp, Cavalier, Roberto&nbsp, Cavalieri, Giancarlo&nbsp, Cella, Pablo&nbsp, Cerdá-Durán, Elisabetta&nbsp, Cesarini, Oualid&nbsp, Chaibi, Kabir&nbsp, Chakravarti, Chiwai&nbsp, Chan, Manleong&nbsp, Chan, Shiuh&nbsp, Chao, Philip&nbsp, Charlton, Eve, Chase, Eric&nbsp, Chassande-Mottin, Deep&nbsp, Chatterjee, Mayank&nbsp, Chaturvedi, Hsin-yu, Chen, Xu&nbsp, Chen, Yanbei&nbsp, Hai-ping&nbsp, Cheng, Chi-kit, Cheong, Hanyu, Chia, Chiadini, Roberto&nbsp, Chierici, Chincarini, Antonino&nbsp, Chiummo, Gihyuk&nbsp, Cho, Heesuk, Cho, Min-a&nbsp, Nelson&nbsp, Christensen, Qi&nbsp, Chu, Sheon&nbsp, Chua, Ka-wai, Chung, Shinkee&nbsp, Chung, Ciani, Pawel&nbsp, Ciecielag, Marek&nbsp, Cieślar, Alexei, Ciobanu, Ciolfi, Cipriano, Alessio&nbsp, Cirone, Filiberto&nbsp, Clara, James, Clark, Clearwater, Clesse, Frederic&nbsp, Cleva, Eugenio&nbsp, Coccia, Pierre-francois&nbsp, Cohadon, Cohen, Marta&nbsp, Colleoni, Christophe, Collette, Christopher&nbsp, Collins, Monica&nbsp, Colpi, Marcio&nbsp, Constancio&nbsp, Livia&nbsp, Jr., Conti, Sam, Cooper, Corban, Thomas, Corbitt, Isabel&nbsp, Cordero-Carrión, Silvia&nbsp, Corezzi, Kenneth, Corley, Neil&nbsp, Cornish, Corre, Corsi, Cortese, Cesar, Costa, Cotesta, Michael, Coughlin, Scott, Coughlin, Jeanpierre&nbsp, Coulon, Stefan, Countryman, Couvares, Pep, Covas, David, Coward, Matthew, Cowart, Dennis, Coyne, Coyne, Jolien, &nbsp, Creighton, Teviet, Creighton, Cripe, Michael&nbsp, Croquette, Sgwynne, Crowder, Jean-rene&nbsp, Cudell, Torrey, Cullen, Alan&nbsp, Cumming, Rebecca&nbsp, Cummings, Liam&nbsp, Cunningham, Elena&nbsp, Cuoco, Malgorzata&nbsp, Curylo, Tito&nbsp, Dal&nbsp, Canton, Gergely&nbsp, Dálya, Aykutlu&nbsp, Dana, Lara, Daneshgaran-Bajastani, Beatrice&nbsp, D’Angelo, Stefan, Danilishin, Sabrina&nbsp, D’Antonio, Karsten&nbsp, Danzmann, Christian&nbsp, Darsow-Fromm, Arnab&nbsp, Dasgupta, Laurence, &nbsp, Datrier, Vincenzo&nbsp, Dattilo, Ishant&nbsp, Dave, Michel&nbsp, Davier, Gareth, Davies, Derek&nbsp, Davis, Edward, Daw, Dan&nbsp, Debra, Malathi&nbsp, Deenadayalan, Jerome&nbsp, Degallaix, Martina&nbsp, De&nbsp, Laurentis, Samuel&nbsp, Deléglise, Matthew&nbsp, Delfavero, Nicola&nbsp, Lillo, Walter&nbsp, Del&nbsp, Pozzo, Lindsay, Demarchi, Virginia&nbsp, D’Emilio, Nicholas&nbsp, Demos, Dent, Pietri, Rosario&nbsp, Rosa, Camilla&nbsp, Rossi, Riccardo&nbsp, Desalvo, Omar&nbsp, de&nbsp, Varona, Sanjeev&nbsp, Dhurandhar, Mario, Díaz, Mauricio&nbsp, Diaz-Ortiz&nbsp, Tim&nbsp, Dietrich, Luciano&nbsp, Di&nbsp, Fiore, Chiara&nbsp, Fronzo, Cinzia&nbsp, Giorgio, Giovanni, Matteo&nbsp, Giovanni, Tristano&nbsp, Girolamo, Alberto&nbsp, Lieto, Binlei&nbsp, Ding, Sibilla&nbsp, Pace, Irene&nbsp, Palma, Renzo, Atul, Divakarla, Artemiy&nbsp, Dmitriev, Zoheyr&nbsp, Doctor, Fred&nbsp, Donovan, Katherine, Dooley, Suresh&nbsp, Doravari, Iain&nbsp, Dorrington, Thomas, Downes, Drago, Jenne, Driggers, Zhihui&nbsp, Jean-gregoire&nbsp, Ducoin, Dupej, Ofelia&nbsp, Durante, Domenico&nbsp, D’Urso, Sheila, Dwyer, Paul, Easter, Graeme&nbsp, Eddolls, Bruce&nbsp, Edelman, Tega, Edo, Oliver&nbsp, Edy, Anamaria&nbsp, Effler, Phil&nbsp, Ehrens, Johannes&nbsp, Eichholz, Stephen, Eikenberry, Eisenmann, Robert, Eisenstein, Aldo&nbsp, Ejlli, Lucianolucianikerrico&nbsp, Errico, Reed, Essick, Hector&nbsp, Estelles, Dimitri&nbsp, Estevez, Zachariah, Etienne, Todd&nbsp, Etzel, Matthew&nbsp, Evans, Tom, Evans, Rebecca, Ewing, Viviana&nbsp, Fafone, Fairhurst, Xilong&nbsp, Fan, Stefania&nbsp, Farinon, Benjamin&nbsp, Farr, Will, Farr, Edward, Fauchon-Jones, Favata, Maxime&nbsp, Fays, Mariana&nbsp, Fazio, Jon&nbsp, Feicht, Martin, Fejer, Fangchen&nbsp, Feng, Edit&nbsp, Fenyvesi, Deborah, Ferguson, Alvaro&nbsp, Fernandez-Galiana, Isidoro&nbsp, Ferrante, Elvis, Ferreira, Tabata, Ferreira, Fidecaro, Irene&nbsp, Fiori, Donatella&nbsp, Fiorucci, Maya&nbsp, Fishbach, Ryan, Fisher, Rosalba&nbsp, Fittipaldi, Margot&nbsp, Fitz-Axen, Vincenzo&nbsp, Fiumara, Raffaele&nbsp, Flaminio, Erik&nbsp, Floden, Flynn, Heather&nbsp, Fong, Antonio, Font, Perry&nbsp, Forsyth, Jean-daniel&nbsp, Fournier, Sergio&nbsp, Frasca, Frasconi, Zsolt&nbsp, Frei, Andreas&nbsp, Freise, Raymond&nbsp, Frey, Valentin&nbsp, Fritschel, Valery, Frolov, Gabriele&nbsp, Fronzè, Fulda, Fyffe, Hunter, Gabbard, Bhooshan, Gadre, Sebastian, Gaebel, Jonathan, Gair, Shanika&nbsp, Galaudage, Dhruva&nbsp, Ganapathy, Sharad, Gaonkar, Cecilio&nbsp, García-Quirós, Garufi, Bubba&nbsp, Gateley, Gaudio, Gayathri&nbsp, Gayathri, Gianluca&nbsp, Gemme, Genin, Alberto&nbsp, Gennai, George, Jogy&nbsp, Laszlo&nbsp, Gergely, Sudarshan&nbsp, Ghonge, Abhirup&nbsp, Ghosh, Archisman&nbsp, Shaon&nbsp, Bruno&nbsp, Giacomazzo, Joe, Giaime, Dwayne, Giardina, Des, Gibson, Chalisa&nbsp, Gier, Kiranjyot&nbsp, Gill, Jane&nbsp, Glanzer, Jan&nbsp, Gniesmer, Godwin, Evan&nbsp, Goetz, Ryan&nbsp, Niklas&nbsp, Gohlke, Boris&nbsp, Goncharov, Gabriela&nbsp, González, Gopakumar&nbsp, Gopakumar, Sarah, Gossan, Matthieu&nbsp, Gosselin, Gouaty, Grace, Aniello&nbsp, Grado, Massimo&nbsp, Granata, Alastair&nbsp, Grant, Slawomir&nbsp, Gras, Grassia, Gray, Rachel&nbsp, Giuseppe&nbsp, Greco, Anna, Green, Rhys&nbsp, Green, Elizabeth, Gretarsson, Hannah, Griggs, nbsp, Grignani, Grimaldi, Stefan, Grimm, Hartmut&nbsp, Grote, Steffen&nbsp, Grunewald, Pierre&nbsp, Gruning, Gianluca, Guidi, Andre, Guimaraes, Gerard&nbsp, Guixé, Hitesh, Gulati, Yuefan&nbsp, Guo, Anuradha&nbsp, Gupta, Anchal&nbsp, Pawan&nbsp, Eric, Gustafson, Dick&nbsp, Gustafson, Leila&nbsp, Haegel, Odysse&nbsp, Halim, Evan, Hall, Eleanor, Hamilton, Giles&nbsp, Hammond, Maria&nbsp, Haney, Manuela, Hanke, Hanks, Chad&nbsp, Hanna, Mark, Hannam, Otto, Hannuksela, Travis, Hansen, Joe&nbsp, Hanson, Harder, Terra&nbsp, Hardwick, Haris&nbsp, Haris, Harms, Gregg, Harry, Ian, Harry, Raine, Hasskew, Carl-johan&nbsp, Haster, Karen&nbsp, Haughian, Fergus, Hayes, James&nbsp, Healy, Antoine&nbsp, Heidmann, Matthew, Heintze, Joscha&nbsp, Heinze, Henrich&nbsp, Heitmann, Frances&nbsp, Hellman, Patrice&nbsp, Hello, Gary&nbsp, Hemming, Martin&nbsp, Hendry, Siong, Heng, Hennes, Jan-simon&nbsp, Hennig, Michele&nbsp, Heurs, Stefan&nbsp, Hild, Tanja&nbsp, Hinderer, Sarah, Hoback, Sven&nbsp, Hochheim, Elyssa&nbsp, Hofgard, Hofman, Aaron, Holgado, Nathan, Holland, Kathy&nbsp, Holt, Daniel, Holz, Hopkins, Horst, Hough, Eric, Howell, Charlie, Hoy, Yiwen&nbsp, Huang, Moritz, Hübner, Eliu, Huerta, Dominique&nbsp, Huet, Brennan&nbsp, Hughey, Victor&nbsp, Hui, Sascha&nbsp, Husa, Sabina, Huttner, Rachael&nbsp, Huxford, Tien&nbsp, Huynh-Dinh, Bartosz&nbsp, Idzkowski, Iess, Henri&nbsp, Inchauspe, Ingram, Intini, Jean, Isac, Max&nbsp, Isi, Bala, Iyer, Thibaut&nbsp, Jacqmin, Sameer, Jadhav, Shreejit, Jadhav, Alasdair, James, Karan&nbsp, Jani, Nagaraj, Janthalur, Piotr&nbsp, Jaranowski, Jariwala, Rafel&nbsp, Jaume, Alex, Jenkins, Jun&nbsp, Jiang, Grace, Johns, Aaron, Jones, Ian, Jones, Jeff, Jones, Philip&nbsp, Jones, Russell&nbsp, Reinier, &nbsp, Jonker, Ju&nbsp, Jonas&nbsp, Junker, Chinmay, Kalaghatgi, Vassiliki&nbsp, Kalogera, Brittany&nbsp, Kamai, Shivaraj&nbsp, Kandhasamy, Gungwon&nbsp, Kang, Jonah, Kanner, Shasvath, Kapadia, Karki, Rahul&nbsp, Kashyap, Marie&nbsp, Kasprzack, Wolfgang&nbsp, Kastaun, Stavros&nbsp, Katsanevas, Katsavounidis, William&nbsp, Katzman, Kaufer, Keita&nbsp, Kawabe, Fabien&nbsp, Kéfélian, Keitel, Azadeh&nbsp, Keivani, Kennedy, Joey, Key, Sudiksha&nbsp, Khadka, Farit, Khalili, Imran&nbsp, Khan, Sebastian&nbsp, Zaki, Khan, Efim, Khazanov, Nandita&nbsp, Khetan, Mohammad&nbsp, Khursheed, Nutsinee&nbsp, Kijbunchoo, Chunglee&nbsp, Kim, Grace, Kim, Jeongcho, Kim, Kyungmin&nbsp, Won&nbsp, Whansun, Kim, Young-min&nbsp, Charles&nbsp, Kimball, Peter, King, Kinley-Hanlon, Robin&nbsp, Kirchhoff, Jeffrey, Kissel, Kleybolte, Sergei&nbsp, Klimenko, Tyler, Knowles, Koch, Sina, Koehlenbeck, Gideon&nbsp, Koekoek, Soumen&nbsp, Koley, Veronica&nbsp, Kondrashov, Antonios&nbsp, Kontos, Nico&nbsp, Koper, Mikhail&nbsp, Korobko, William, Korth, Manoj&nbsp, Kovalam, Dan, Kozak, Volker&nbsp, Kringel, Krishnendu, Nv, Andrzej&nbsp, Królak, Natalie&nbsp, Krupinski, Gerrit&nbsp, Kuehn, Anil&nbsp, Kumar, Prayush&nbsp, Rakesh&nbsp, Sumit&nbsp, Ling-chi&nbsp, Kuo, Adam&nbsp, Kutynia, Benjamin, Lackey, Danny&nbsp, Laghi, Emile&nbsp, Lalande, Lam, Lam, Astrid&nbsp, Lamberts, Landry, Benjamin, Lane, Ryan, Lang, Jacob&nbsp, Lange, Brian&nbsp, Lantz, Robert, Lanza, Iuri&nbsp, La&nbsp, Rosa, Angelique&nbsp, Lartaux-Vollard, Paul, Lasky, Laxen, Albert&nbsp, Lazzarini, Claudia&nbsp, Lazzaro, Paola&nbsp, Leaci, Sean&nbsp, Leavey, Yannick, Lecoeuche, Chang-hwan, Lee, Hyung-mok, Lee, Hyungwon, Lee, Joongoo&nbsp, Lee, Kyung-ha&nbsp, Lehmann, Leroy, Letendre, Yuri&nbsp, Levin, Alvin, &nbsp, Jin&nbsp, Kaye&nbsp, Tjonnie, &nbsp, Xiang&nbsp, Frank&nbsp, Linde, Seth, Linker, Jethro, Linley, Tyson, Littenberg, Liu&nbsp, Liu, Xiaoshu&nbsp, Miquel&nbsp, Llorens-Monteagudo, Ka-lok&nbsp, Alexandra&nbsp, Lockwood, Lionel, London, Longo, Lorenzini, Vincent&nbsp, Loriette, Lormand, Losurdo, James, Lough, Carlos, Lousto, Geoffrey&nbsp, Lovelace, Harald&nbsp, Lück, Diana&nbsp, Lumaca, Andrew, Lundgren, Ma&nbsp, Yiqiu, Ronaldas&nbsp, Macas, Macfoy, Myron&nbsp, Macinnis, Duncan, Macleod, Ian, Macmillan, Adrian&nbsp, Macquet, Ignacio&nbsp, Magaña&nbsp, Hernandez, Fabian&nbsp, Magaña-Sandoval, Ryan, Magee, Ettore&nbsp, Majorana, Ivan&nbsp, Maksimovic, Asmita&nbsp, Malik, Catherine&nbsp, Man, Vuk&nbsp, Mandic, Valentina&nbsp, Mangano, Georgia, Mansell, Manske, Maddalena&nbsp, Mantovani, Michela&nbsp, Mapelli, Marchesoni, Frederique&nbsp, Marion, Szabolcs&nbsp, Márka, Zsuzsanna&nbsp, Charalampos&nbsp, Markakis, Ashot, Markosyan, Markowitz, Ed&nbsp, Maros, Antonio&nbsp, Marquina, Sylvain&nbsp, Marsat, Filippo&nbsp, Martelli, Ian, Martin, Rodica, Martin, Martinez, Denis, Martynov, Hossein&nbsp, Masalehdan, Ken&nbsp, Mason, Massera, Masserot, Thomas, Massinger, Mariela&nbsp, Masso-Reid, Simone&nbsp, Mastrogiovanni, Andrew&nbsp, Matas, Fabrice&nbsp, Matichard, Nergis&nbsp, Mavalvala, Emily&nbsp, Maynard, Joshua, Mccann, Richard&nbsp, Mccarthy, David, Mcclelland, Scott&nbsp, Mccormick, Lee&nbsp, Mcculler, Stephen, Mcguire, Connor&nbsp, Mcisaac, Jessica&nbsp, Mciver, David, Mcmanus, Terry&nbsp, Mcrae, Sean, Mcwilliams, Duncan&nbsp, Meacher, Grant, Meadors, Moritz&nbsp, Mehmet, Ajit, Mehta, Mejuto&nbsp, Villa, Andrew&nbsp, Melatos, Gregory&nbsp, Mendell, Adam, Mercer, Mereni, Kara&nbsp, Merfeld, Edmond, Merilh, Jonathan, Merritt, Mourad&nbsp, Merzougui, Syd&nbsp, Meshkov, Chris&nbsp, Messenger, Cody&nbsp, Messick, Remi&nbsp, Metzdorff, Patrick, Meyers, Fabian&nbsp, Meylahn, Ashish&nbsp, Mhaske, Miani, Haixing&nbsp, Miao, Ioannis&nbsp, Michaloliakos, Christophe&nbsp, Michel, Hannah&nbsp, Middleton, Leopoldo&nbsp, Milano, Andrewlawrence, Miller, Meg&nbsp, Millhouse, Joseph, Mills, Edoardo&nbsp, Milotti, Michael, Milovich-Goff, Olivier&nbsp, Minazzoli, Minenkov, Alec&nbsp, Mishkin, Chandra&nbsp, Mishra, Timesh&nbsp, Mistry, Sanjit&nbsp, Mitra, Valery, Mitrofanov, Guenakh&nbsp, Mitselmakher, Mittleman, Kentaro&nbsp, Mogushi, Satyanarayan, &nbsp, Mohapatra, Siddharth, Mohite, Manel&nbsp, Molina-Ruiz, Marina&nbsp, Mondin, Montani, Christopher, Moore, Moraru, Filip&nbsp, Morawski, Gerardo&nbsp, Moreno, Soichiro&nbsp, Morisaki, Benoit&nbsp, Mours, Conor, Mow-Lowry, Mozzon, Federico&nbsp, Muciaccia, Arunava&nbsp, Mukherjee, Debnandini&nbsp, Soma&nbsp, Subroto&nbsp, Nikhil&nbsp, Mukund, Mullavey, Jesper&nbsp, Munch, Erik, Muñiz, Peter, Murray, Nagar, Ilaria&nbsp, Nardecchia, Luca&nbsp, Naticchioni, Rajesh, Nayak, Benjamin, Neil, Joshua&nbsp, Neilson, Gijs&nbsp, Nelemans, Timothy, &nbsp, Nelson, Marina&nbsp, Nery, Ansel&nbsp, Neunzert, Kwan-yeung, Ng, Nguyen, Nichols, Shania, Nichols, Samaya&nbsp, Nissanke, Flavio&nbsp, Nocera, Minkyun&nbsp, Noh, North, Devon&nbsp, Nothard, Laura, Nuttall, Jason&nbsp, Oberling, Brendan, O’Brien, Gor&nbsp, Oganesyan, Greg, Ogin, John, Oh, Sanghoon, Oh, Ohme, Hiroaki&nbsp, Ohta, Marcos, Okada, Oliver, Olivetto, Oppermann, Oram, O’Reilly, Rich, Ormiston, Luis, Ortega, O’Shaughnessy, Serguei&nbsp, Ossokine, Osthelder, David, Ottaway, Harry&nbsp, Overmier, Ben, Owen, Alexander, Pace, Giulia&nbsp, Pagano, Michael, Page, Pagliaroli, Archana&nbsp, Pai, Siddhesh, Pai, Jordan, Palamos, Oleg&nbsp, Palashov, Cristiano&nbsp, Palomba, Howard&nbsp, Pan, Pratap, Panda, Tsun-ho&nbsp, Pang, Pankow, Pannarale, F, Brijesh, Pant, Paoletti, Paoli, Abhishek&nbsp, Parida, Parker, Daniela&nbsp, Pascucci, Pasqualetti, Passaquieti, Passuello, Barbara&nbsp, Patricelli, Ethan&nbsp, Payne, Brynley, Pearlstone, Thida, Pechsiri, Ari, Pedersen, Mike&nbsp, Pedraza, Arnaud&nbsp, Pele, Steven&nbsp, Penn, Albino&nbsp, Perego, Carlos, Perez, Perigois&nbsp, Périgois, Perreca, Stephane&nbsp, Perriès, Petermann, Harald, Pfeiffer, Phelps, Khun, Phukon, Ornella, Piccinni, Mikhael&nbsp, Pichot, Piendibene, Piergiovanni, Pierro, Gabriel&nbsp, Pillant, Laurent&nbsp, Pinard, Innocenzo, Pinto, Krzysztof&nbsp, Piotrzkowski, Pirello, Pitkin, Wolfango&nbsp, Plastino, Rosa&nbsp, Poggiani, Yat-tung, Pong, Ponrathnam, Pasquale&nbsp, Popolizio, Porter, Ed, Jade&nbsp, Powell, Atul, Prajapati, Kiran&nbsp, Prasai, Raghurama&nbsp, Prasanna, Geraint&nbsp, Pratten, Tanner&nbsp, Prestegard, Principe, Prodi, Leonid&nbsp, Prokhorov, Punturo, Puppo, Pürrer, Hong&nbsp, Quetschke, Pedro, Quinonez, Fred, Raab, Geert&nbsp, Raaijmakers, Hugh&nbsp, Radkins, Radulesco, Raffai, Hanna&nbsp, Rafferty, Sendhil&nbsp, Raja, Rajan&nbsp, Rajan, Binod&nbsp, Rajbhandari, Malik&nbsp, Rakhmanov, Karla, Ramirez, Antoni&nbsp, Ramos-Buades, Javed&nbsp, Rana, Kaushik&nbsp, Rao, Piero&nbsp, Rapagnani, Vivien&nbsp, Raymond, Razzano, Jocelyn&nbsp, Read, Tania&nbsp, Regimbau, Rei, Reid, David, Reitze, Rettegno, Fulvio&nbsp, Ricci, Colter, Richardson, Jonathan, Richardson, Paul, Ricker, Gunnar&nbsp, Riemenschneider, Keith&nbsp, Riles, Rizzo, Norna, Robertson, Florent&nbsp, Robinet, Rocchi, Ramon, Rodriguez-Soto, Loic&nbsp, Rolland, Jameson, Rollins, Vincent, Roma, Romanelli, Rocco&nbsp, Romano, Chandra, Romel, Isobel, Romero-Shaw, Janeen, Romie, Caitlin, Rose, Dakota&nbsp, Rose, Kyle&nbsp, Dorota&nbsp, Rosińska, Shawn, Rosofsky, Michael, Ross, Sheila&nbsp, Rowan, Samuel, Rowlinson, Palash, Roy, Santosh&nbsp, Roy, Paolo&nbsp, Ruggi, Guntis&nbsp, Rutins, Ryan, Surabhi&nbsp, Sachdev, Travis&nbsp, Sadecki, Mairi&nbsp, Sakellariadou, Salafia, Om, Livio&nbsp, Salconi, Muhammed&nbsp, Saleem, Samajdar, Eduardo, Sanchez, Luis, Sanchez, Sanchis-Gual, Jaclyn, Sanders, Kevin, Santiago, Edison&nbsp, Santos, Sarin, Sassolas, Sathyaprakash, B, Orion&nbsp, Sauter, Richard, Savage, Vaibhav&nbsp, Savant, Disha&nbsp, Sawant, Sihem&nbsp, Sayah, Dean&nbsp, Schaetzl, Schale, Mark&nbsp, Scheel, Scheuer, Patricia&nbsp, Schmidt, Roman&nbsp, Schnabel, Robert, &nbsp, Schofield, Axel&nbsp, Schönbeck, Emil&nbsp, Schreiber, Bernd, Schulte, Bernard, Schutz, Otto&nbsp, Schwarm, Eyal&nbsp, Schwartz, Jamie&nbsp, Scott, Susan, Scott, Seidel, Sellers, Anand, Sengupta, Noah&nbsp, Sennett, Sentenac, Valeria&nbsp, Sequino, Sergeev, Yoshinta&nbsp, Setyawati, Daniel, Shaddock, Shaffer, Selim, Shahriar, Sharma, Priyanka&nbsp, Shawhan, Hongyu&nbsp, Shen, Minori&nbsp, Shikauchi, Rosalie&nbsp, Shink, David, Shoemaker, Deirdre, Shoemaker, Keerti&nbsp, Shukla, Shyamsundar&nbsp, Shyamsundar, Karelle&nbsp, Siellez, Magdalena&nbsp, Sieniawska, Sigg, Leo, Singer, Divya&nbsp, Singh, Neha&nbsp, Ayatri&nbsp, Singha, Akshat&nbsp, Singhal, Alicia, Sintes, Sipala, Vasileios&nbsp, Skliris, Bram, &nbsp, Slagmolen, Teresa, Slaven-Blair, Jiri&nbsp, Smetana, Joshua, Smith, Rory, &nbsp, Smith, Surendranadh&nbsp, Somala, Edwin, Son, Siddharth&nbsp, Soni, Borja&nbsp, Sorazu, Viola&nbsp, Sordini, Fiodor&nbsp, Sorrentino, Tarun&nbsp, Souradeep, Sowell, Andrew, Spencer, Mario&nbsp, Spera, Amit, Srivastava, Varun&nbsp, Srivastava, Kai&nbsp, Staats, Cosmin&nbsp, Stachie, Standke, Daniele, Steer, Steinke, Steinlechner, Steinmeyer, Dane&nbsp, Stocks, David, Stops, Madeline&nbsp, Stover, Ken, Strain, Stratta, Amber&nbsp, Strunk, Sturani, Amber, Stuver, Sudhagar&nbsp, Sudhagar, Vivishek&nbsp, Sudhir, Tiffany, Summerscales, Ling&nbsp, Sun, Sunil&nbsp, Sunil, Ankan&nbsp, Sur, Jishnu&nbsp, Suresh, Patrick, Sutton, Bas, Swinkels, Marek, Szczepańczyk, Tacca, Simon, Tait, Colm&nbsp, Talbot, Andres, Tanasijczuk, David, Tanner, Duo&nbsp, Tao, Marton&nbsp, Tápai, Amauri&nbsp, Tapia, Enzo, Tapia&nbsp, San&nbsp, Martin, Jay, Tasson, Taylor, Rodrigo&nbsp, Tenorio, Lukas&nbsp, Terkowski, Manasadevi, Thirugnanasambandam, Thomas, Jonathan, Thompson, Sivananda, Thondapu, Keith, Thorne, Thrane, Calley, Tinsman, Saravanan, Saravanan, Shubhanshu&nbsp, Tiwari, Srishti&nbsp, Karl&nbsp, Toland, Mauro&nbsp, Tonelli, Zeno&nbsp, Tornasi, Alejandro&nbsp, Torres-Forné, Calum, Torrie, Iara&nbsp, Tosta&nbsp, e&nbsp, Melo, Töyrä, Emily, Trail, Travasso, Traylor, Maria, Tringali, Aashish&nbsp, Tripathee, Agata&nbsp, Trovato, Randy, Trudeau, Ka-wa, Tsang, Maggie&nbsp, Tse, Rhondale&nbsp, Tso, Leo&nbsp, Tsukada, Daichi&nbsp, Tsuna, Takuya&nbsp, Tsutsui, Margherita&nbsp, Turconi, Amit, Ubhi, Koh&nbsp, Ueno, Dennis&nbsp, Ugolini, Unnikrishnan, Cs, Alexander, Urban, Samantha, Usman, Andrei, Utina, Henning&nbsp, Vahlbruch, Vajente, Guillermo&nbsp, Valdes, Valentini, Vallisneri, Niels&nbsp, van&nbsp, Bakel, Martin&nbsp, Beuzekom, den&nbsp, Brand, Chris&nbsp, Van&nbsp, Den&nbsp, Broeck, Daniel, Vander-Hyde, der&nbsp, Schaaf, Joris, Van&nbsp, Heijningen, Marielle, van&nbsp, Veggel, Marco&nbsp, Vardaro, Vijay&nbsp, Varma, Steve&nbsp, Vass, Matyas&nbsp, Vasúth, Alberto&nbsp, Vecchio, Gabriele&nbsp, Vedovato, John&nbsp, Veitch, Peter, Veitch, Krishna&nbsp, Venkateswara, Gautam&nbsp, Venugopalan, Didier&nbsp, Verkindt, Doga&nbsp, Veske, Vetrano, Viceré, Aaron, Viets, Serena&nbsp, Vinciguerra, David, Vine, Jeanyves&nbsp, Vinet, Salvatore&nbsp, Vitale, Francisco&nbsp, Hernandez&nbsp, Vivanco, Thomas&nbsp, Helios&nbsp, Vocca, Cheryl&nbsp, Vorvick, Sergey, Vyatchanin, Andrew, Wade, Leslie, Wade, Wade, Rob&nbsp, Walet, Marissa&nbsp, Walker, Gavin, Wallace, Larry&nbsp, Wallace, Sinead&nbsp, Walsh, Jonathan, Wang, Sibo&nbsp, Wang, Wenhui, Wang, Yifan, Wang, Robert, Ward, Zane, Warden, Jim&nbsp, Warner, Was, Jennifer&nbsp, Watchi, Betsy&nbsp, Weaver, Li-wei&nbsp, Wei, Weinert, Alan, Weinstein, Rainer&nbsp, Weiss, Felix&nbsp, Wellmann, Linqing&nbsp, Wen, Weßels, Jonathan, Westhouse, Wette, John, Whelan, Bernard, Whiting, Whittle, Dennis, Wilken, Williams, Roy, Williams, Andrew, Williamson, Joshua, Willis, Benno&nbsp, Willke, Winkler, Christopher, Wipf, Holger&nbsp, Wittel, Graham&nbsp, Woan, Janis&nbsp, Woehler, Jared, Wofford, Chun-fung&nbsp, Wong, Jennifer, Wright, David, Wu, Daniel, Wysocki, Liting&nbsp, Xiao, Hiro&nbsp, Yamamoto, Le&nbsp, Yang, Yang&nbsp, Ziyan&nbsp, Min-jet, Yap, Maher&nbsp, Yazback, David, Yeeles, Hang&nbsp, Haocun&nbsp, Shingheirobin&nbsp, Yuen, Adam, Zadrożny, Zadrożny, Zanolin, Tatiana&nbsp, Zelenova, Jean-pierre&nbsp, Zendri, Zevin, Jue&nbsp, Zhang, Liyuan&nbsp, Teng&nbsp, Chunnong&nbsp, Zhao, Guoying&nbsp, Minchuan&nbsp, Zhou, Zifan&nbsp, Xingjiang, Zhu, Aaron, Zimmerman, Michael, Zucker, John&nbsp, Zweizig, Laboratoire des matériaux avancés (LMA), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Centre National de la Recherche Scientifique (CNRS), Institut de Physique des 2 Infinis de Lyon (IP2I Lyon), AstroParticule et Cosmologie (APC (UMR_7164)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Observatoire de Paris, Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité), Laboratoire de l'Accélérateur Linéaire (LAL), Université Paris-Sud - Paris 11 (UP11)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Centre National de la Recherche Scientifique (CNRS), Laboratoire d'Annecy de Physique des Particules (LAPP), Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Université Savoie Mont Blanc (USMB [Université de Savoie] [Université de Chambéry])-Centre National de la Recherche Scientifique (CNRS), Astrophysique Relativiste Théories Expériences Métrologie Instrumentation Signaux (ARTEMIS), Université Nice Sophia Antipolis (1965 - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Institut national des sciences de l'Univers (INSU - CNRS)-Observatoire de la Côte d'Azur, COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Université Côte d'Azur (UCA)-Université Côte d'Azur (UCA)-Centre National de la Recherche Scientifique (CNRS), Institut des Fonctions Optiques pour les Technologies de l'informatiON (Institut FOTON), Université de Rennes (UR)-Institut National des Sciences Appliquées - Rennes (INSA Rennes), Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-École Nationale Supérieure des Sciences Appliquées et de Technologie (ENSSAT)-Centre National de la Recherche Scientifique (CNRS), Laboratoire Kastler Brossel (LKB [Collège de France]), Fédération de recherche du Département de physique de l'Ecole Normale Supérieure - ENS Paris (FRDPENS), École normale supérieure - Paris (ENS-PSL), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Centre National de la Recherche Scientifique (CNRS)-École normale supérieure - Paris (ENS-PSL), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Centre National de la Recherche Scientifique (CNRS)-Collège de France (CdF (institution))-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Institut Lumière Matière [Villeurbanne] (ILM), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS), Observatoire de la Côte d'Azur (OCA), Institut national des sciences de l'Univers (INSU - CNRS)-Centre National de la Recherche Scientifique (CNRS), Ecole Superieure de Physique et de Chimie Industrielles de la Ville de Paris (ESPCI Paris), Université Paris sciences et lettres (PSL), Institut Pluridisciplinaire Hubert Curien (IPHC), Université de Strasbourg (UNISTRA)-Université de Haute-Alsace (UHA) Mulhouse - Colmar (Université de Haute-Alsace (UHA))-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Centre National de la Recherche Scientifique (CNRS), Institut des Hautes Études Scientifiques (IHES), IHES, LIGO Scientific, Virgo, (Astro)-Particles Physics, LIGO Scientific Collaboration, Virgo Collaboration, Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Université Claude Bernard Lyon 1 (UCBL), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Centre National de la Recherche Scientifique (CNRS)-Université de Paris (UP), Centre National de la Recherche Scientifique (CNRS)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Université Paris-Sud - Paris 11 (UP11), Centre National de la Recherche Scientifique (CNRS)-Observatoire de la Côte d'Azur, Université Côte d'Azur (UCA)-COMUE Université Côte d'Azur (2015 - 2019) (COMUE UCA)-Université Côte d'Azur (UCA)-COMUE Université Côte d'Azur (2015 - 2019) (COMUE UCA)-Institut national des sciences de l'Univers (INSU - CNRS)-Université Nice Sophia Antipolis (... - 2019) (UNS), COMUE Université Côte d'Azur (2015 - 2019) (COMUE UCA), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Centre National de la Recherche Scientifique (CNRS)-Institut National des Sciences Appliquées - Rennes (INSA Rennes), Institut National des Sciences Appliquées (INSA)-Université de Rennes (UNIV-RENNES)-Institut National des Sciences Appliquées (INSA)-IMT Atlantique Bretagne-Pays de la Loire (IMT Atlantique), Institut Mines-Télécom [Paris] (IMT)-Institut Mines-Télécom [Paris] (IMT)-École Nationale Supérieure des Sciences Appliquées et de Technologie (ENSSAT), École normale supérieure - Paris (ENS Paris), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Centre National de la Recherche Scientifique (CNRS)-Fédération de recherche du Département de physique de l'Ecole Normale Supérieure - ENS Paris (FRDPENS), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Centre National de la Recherche Scientifique (CNRS)-Centre National de la Recherche Scientifique (CNRS)-Sorbonne Université (SU)-Collège de France (CdF (institution)), Spectroscopies optiques des matériaux verres, amorphes et à nanoparticules (SOPRANO), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Université de Strasbourg (UNISTRA)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Centre National de la Recherche Scientifique (CNRS), Institut des Hautes Etudes Scientifiques (IHES), Agencia Estatal de Investigación (España), Generalitat de Catalunya, Generalitat Valenciana, European Commission, Grav. waves and fundamental physics, RS: FSE Grav. waves and fundamental physics, RS: FSE MSP, Abbott, R., Abbott, T. D., Abraham, S., Acernese, F., Ackley, K., Adams, C., Adhikari, R. X., Adya, V. B., Affeldt, C., Agathos, M., Agatsuma, K., Aggarwal, N., Aguiar, O. D., Aich, A., Aiello, L., Ain, A., Ajith, P., Allen, G., Allocca, A., Altin, P. A., Amato, A., Anand, S., Ananyeva, A., Anderson, S. B., Anderson, W. G., Angelova, S. V., Ansoldi, S., Antier, S., Appert, S., Arai, K., Araya, M. C., Areeda, J. S., Arène, M., Arnaud, N., Aronson, S. M., Arun, K. G., Ascenzi, S., Ashton, G., Aston, S. M., Astone, P., Aubin, F., Aufmuth, P., Aultoneal, K., Austin, C., Avendano, V., Babak, S., Bacon, P., Badaracco, F., Bader, M. K. M., Bae, S., Baer, A. M., Baird, J., Baldaccini, F., Ballardin, G., Ballmer, S. W., Bals, A., Balsamo, A., Baltus, G., Banagiri, S., Bankar, D., Bankar, R. S., Barayoga, J. C., Barbieri, C., Barish, B. C., Barker, D., Barkett, K., Barneo, P., Barone, F., Barr, B., Barsotti, L., Barsuglia, M., Barta, D., Bartlett, J., Bartos, I., Bassiri, R., Basti, A., Bawaj, M., Bayley, J. C., Bazzan, M., Bécsy, B., Bejger, M., Belahcene, I., Bell, A. S., Beniwal, D., Benjamin, M. G., Bentley, J. D., Bergamin, F., Berger, B. K., Bergmann, G., Bernuzzi, S., Berry, C. P. L., Bersanetti, D., Bertolini, A., Betzwieser, J., Bhandare, R., Bhandari, A. V., Bidler, J., Biggs, E., Bilenko, I. A., Billingsley, G., Birney, R., Birnholtz, O., Biscans, S., Bischi, M., Biscoveanu, S., Bisht, A., Bissenbayeva, G., Bitossi, M., Bizouard, M. A., Blackburn, J. K., Blackman, J., Blair, C. D., Blair, D. G., Blair, R. M., Bobba, F., Bode, N., Boer, M., Boetzel, Y., Bogaert, G., Bondu, F., Bonilla, E., Bonnand, R., Booker, P., Boom, B. A., Bork, R., Boschi, V., Bose, S., Bossilkov, V., Bosveld, J., Bouffanais, Y., Bozzi, A., Bradaschia, C., Brady, P. R., Bramley, A., Branchesi, M., Brau, J. E., Breschi, M., Briant, T., Briggs, J. H., Brighenti, F., Brillet, A., Brinkmann, M., Brockill, P., Brooks, A. F., Brooks, J., Brown, D. D., Brunett, S., Bruno, G., Bruntz, R., Buikema, A., Bulik, T., Bulten, H. J., Buonanno, A., Buskulic, D., Byer, R. L., Cabero, M., Cadonati, L., Cagnoli, G., Cahillane, C., Bustillo, J. Calderón, Callaghan, J. D., Callister, T. A., Calloni, E., Camp, J. B., Canepa, M., Cannon, K. C., Cao, H., Cao, J., Carapella, G., Carbognani, F., Caride, S., Carney, M. F., Carullo, G., Diaz, J. Casanueva, Casentini, C., Castañeda, J., Caudill, S., Cavaglià, M., Cavalier, F., Cavalieri, R., Cella, G., Cerdá-Durán, P., Cesarini, E., Chaibi, O., Chakravarti, K., Chan, C., Chan, M., Chao, S., Charlton, P., Chase, E. A., Chassande-Mottin, E., Chatterjee, D., Chaturvedi, M., Chen, H. Y., Chen, X., Chen, Y., Cheng, H. -P., Cheong, C. K., Chia, H. Y., Chiadini, F., Chierici, R., Chincarini, A., Chiummo, A., Cho, G., Cho, H. S., Cho, M., Christensen, N., Chu, Q., Chua, S., Chung, K. W., Chung, S., Ciani, G., Ciecielag, P., Cieślar, M., Ciobanu, A. A., Ciolfi, R., Cipriano, F., Cirone, A., Clara, F., Clark, J. A., Clearwater, P., Clesse, S., Cleva, F., Coccia, E., Cohadon, P. -F., Cohen, D., Colleoni, M., Collette, C. G., Collins, C., Colpi, M., Constancio, M., Conti, L., Cooper, S. J., Corban, P., Corbitt, T. R., Cordero-Carrión, I., Corezzi, S., Corley, K. R., Cornish, N., Corre, D., Corsi, A., Cortese, S., Costa, C. A., Cotesta, R., Coughlin, M. W., Coughlin, S. B., Coulon, J. -P., Countryman, S. T., Couvares, P., Covas, P. B., Coward, D. M., Cowart, M. J., Coyne, D. C., Coyne, R., Creighton, J. D. E., Creighton, T. D., Cripe, J., Croquette, M., Crowder, S. G., Cudell, J. -R., Cullen, T. J., Cumming, A., Cummings, R., Cunningham, L., Cuoco, E., Curylo, M., Canton, T. Dal, Dálya, G., Dana, A., Daneshgaran-Bajastani, L. M., D’Angelo, B., Danilishin, S. L., D’Antonio, S., Danzmann, K., Darsow-Fromm, C., Dasgupta, A., Datrier, L. E. H., Dattilo, V., Dave, I., Davier, M., Davies, G. S., Davis, D., Daw, E. J., Debra, D., Deenadayalan, M., Degallaix, J., De Laurentis, M., Deléglise, S., Delfavero, M., De Lillo, N., Del Pozzo, W., Demarchi, L. M., D’Emilio, V., Demos, N., Dent, T., De Pietri, R., De Rosa, R., De Rossi, C., Desalvo, R., de Varona, O., Dhurandhar, S., Díaz, M. C., Diaz-Ortiz, M., Dietrich, T., Di Fiore, L., Di Fronzo, C., Di Giorgio, C., Di Giovanni, F., Di Giovanni, M., Di Girolamo, T., Di Lieto, A., Ding, B., Di Pace, S., Di Palma, I., Di Renzo, F., Divakarla, A. K., Dmitriev, A., Doctor, Z., Donovan, F., Dooley, K. L., Doravari, S., Dorrington, I., Downes, T. P., Drago, M., Driggers, J. C., Du, Z., Ducoin, J. -G., Dupej, P., Durante, O., D’Urso, D., Dwyer, S. E., Easter, P. J., Eddolls, G., Edelman, B., Edo, T. B., Edy, O., Effler, A., Ehrens, P., Eichholz, J., Eikenberry, S. S., Eisenmann, M., Eisenstein, R. A., Ejlli, A., Errico, L., Essick, R. C., Estelles, H., Estevez, D., Etienne, Z. B., Etzel, T., Evans, M., Evans, T. M., Ewing, B. E., Fafone, V., Fairhurst, S., Fan, X., Farinon, S., Farr, B., Farr, W. M., Fauchon-Jones, E. J., Favata, M., Fays, M., Fazio, M., Feicht, J., Fejer, M. M., Feng, F., Fenyvesi, E., Ferguson, D. L., Fernandez-Galiana, A., Ferrante, I., Ferreira, E. C., Ferreira, T. A., Fidecaro, F., Fiori, I., Fiorucci, D., Fishbach, M., Fisher, R. P., Fittipaldi, R., Fitz-Axen, M., Fiumara, V., Flaminio, R., Floden, E., Flynn, E., Fong, H., Font, J. A., Forsyth, P. W. F., Fournier, J. -D., Frasca, S., Frasconi, F., Frei, Z., Freise, A., Frey, R., Frey, V., Fritschel, P., Frolov, V. V., Fronzè, G., Fulda, P., Fyffe, M., Gabbard, H. A., Gadre, B. U., Gaebel, S. M., Gair, J. R., Galaudage, S., Ganapathy, D., Gaonkar, S. G., García-Quirós, C., Garufi, F., Gateley, B., Gaudio, S., Gayathri, V., Gemme, G., Genin, E., Gennai, A., George, D., George, J., Gergely, L., Ghonge, S., Ghosh, Abhirup, Ghosh, Archisman, Ghosh, S., Giacomazzo, B., Giaime, J. A., Giardina, K. D., Gibson, D. R., Gier, C., Gill, K., Glanzer, J., Gniesmer, J., Godwin, P., Goetz, E., Goetz, R., Gohlke, N., Goncharov, B., González, G., Gopakumar, A., Gossan, S. E., Gosselin, M., Gouaty, R., Grace, B., Grado, A., Granata, M., Grant, A., Gras, S., Grassia, P., Gray, C., Gray, R., Greco, G., Green, A. C., Green, R., Gretarsson, E. M., Griggs, H. L., Grignani, G., Grimaldi, A., Grimm, S. J., Grote, H., Grunewald, S., Gruning, P., Guidi, G. M., Guimaraes, A. R., Guixé, G., Gulati, H. K., Guo, Y., Gupta, A., Gupta, Anchal, Gupta, P., Gustafson, E. K., Gustafson, R., Haegel, L., Halim, O., Hall, E. D., Hamilton, E. Z., Hammond, G., Haney, M., Hanke, M. M., Hanks, J., Hanna, C., Hannam, M. D., Hannuksela, O. A., Hansen, T. J., Hanson, J., Harder, T., Hardwick, T., Haris, K., Harms, J., Harry, G. M., Harry, I. W., Hasskew, R. K., Haster, C. -J., Haughian, K., Hayes, F. J., Healy, J., Heidmann, A., Heintze, M. C., Heinze, J., Heitmann, H., Hellman, F., Hello, P., Hemming, G., Hendry, M., Heng, I. S., Hennes, E., Hennig, J., Heurs, M., Hild, S., Hinderer, T., Hoback, S. Y., Hochheim, S., Hofgard, E., Hofman, D., Holgado, A. M., Holland, N. A., Holt, K., Holz, D. E., Hopkins, P., Horst, C., Hough, J., Howell, E. J., Hoy, C. G., Huang, Y., Hübner, M. T., Huerta, E. A., Huet, D., Hughey, B., Hui, V., Husa, S., Huttner, S. H., Huxford, R., Huynh-Dinh, T., Idzkowski, B., Iess, A., Inchauspe, H., Ingram, C., Intini, G., Isac, J. - M., Isi, M., Iyer, B. R., Jacqmin, T., Jadhav, S. J., Jadhav, S. P., James, A. L., Jani, K., Janthalur, N. N., Jaranowski, P., Jariwala, D., Jaume, R., Jenkins, A. C., Jiang, J., Johns, G. R., Jones, A. W., Jones, D. I., Jones, J. D., Jones, P., Jones, R., Jonker, R. J. G., Ju, L., Junker, J., Kalaghatgi, C. V., Kalogera, V., Kamai, B., Kandhasamy, S., Kang, G., Kanner, J. B., Kapadia, S. J., Karki, S., Kashyap, R., Kasprzack, M., Kastaun, W., Katsanevas, S., Katsavounidis, E., Katzman, W., Kaufer, S., Kawabe, K., Kéfélian, F., Keitel, D., Keivani, A., Kennedy, R., Key, J. S., Khadka, S., Khalili, F. Y., Khan, I., Khan, S., Khan, Z. A., Khazanov, E. A., Khetan, N., Khursheed, M., Kijbunchoo, N., Kim, Chunglee, Kim, G. J., Kim, J. C., Kim, K., Kim, W., Kim, W. S., Kim, Y. -M., Kimball, C., King, P. J., Kinley-Hanlon, M., Kirchhoff, R., Kissel, J. S., Kleybolte, L., Klimenko, S., Knowles, T. D., Koch, P., Koehlenbeck, S. M., Koekoek, G., Koley, S., Kondrashov, V., Kontos, A., Koper, N., Korobko, M., Korth, W. Z., Kovalam, M., Kozak, D. B., Kringel, V., Krishnendu, N. V., Królak, A., Krupinski, N., Kuehn, G., Kumar, A., Kumar, P., Kumar, Rahul, Kumar, Rakesh, Kumar, S., Kuo, L., Kutynia, A., Lackey, B. D., Laghi, D., Lalande, E., Lam, T. L., Lamberts, A., Landry, M., Lane, B. B., Lang, R. N., Lange, J., Lantz, B., Lanza, R. K., La Rosa, I., Lartaux-Vollard, A., Lasky, P. D., Laxen, M., Lazzarini, A., Lazzaro, C., Leaci, P., Leavey, S., Lecoeuche, Y. K., Lee, C. H., Lee, H. M., Lee, H. W., Lee, J., Lee, K., Lehmann, J., Leroy, N., Letendre, N., Levin, Y., Li, A. K. Y., Li, J., Li, K., Li, T. G. F., Li, X., Linde, F., Linker, S. D., Linley, J. N., Littenberg, T. B., Liu, J., Liu, X., Llorens-Monteagudo, M., Lo, R. K. L., Lockwood, A., London, L. T., Longo, A., Lorenzini, M., Loriette, V., Lormand, M., Losurdo, G., Lough, J. D., Lousto, C. O., Lovelace, G., Lück, H., Lumaca, D., Lundgren, A. P., Ma, Y., Macas, R., Macfoy, S., Macinnis, M., Macleod, D. M., Macmillan, I. A. O., Macquet, A., Hernandez, I. Magaña, Magaña-Sandoval, F., Magee, R. M., Majorana, E., Maksimovic, I., Malik, A., Man, N., Mandic, V., Mangano, V., Mansell, G. L., Manske, M., Mantovani, M., Mapelli, M., Marchesoni, F., Marion, F., Márka, S., Márka, Z., Markakis, C., Markosyan, A. S., Markowitz, A., Maros, E., Marquina, A., Marsat, S., Martelli, F., Martin, I. W., Martin, R. M., Martinez, V., Martynov, D. V., Masalehdan, H., Mason, K., Massera, E., Masserot, A., Massinger, T. J., Masso-Reid, M., Mastrogiovanni, S., Matas, A., Matichard, F., Mavalvala, N., Maynard, E., Mccann, J. J., Mccarthy, R., Mcclelland, D. E., Mccormick, S., Mcculler, L., Mcguire, S. C., Mcisaac, C., Mciver, J., Mcmanus, D. J., Mcrae, T., Mcwilliams, S. T., Meacher, D., Meadors, G. D., Mehmet, M., Mehta, A. K., Villa, E. Mejuto, Melatos, A., Mendell, G., Mercer, R. A., Mereni, L., Merfeld, K., Merilh, E. L., Merritt, J. D., Merzougui, M., Meshkov, S., Messenger, C., Messick, C., Metzdorff, R., Meyers, P. M., Meylahn, F., Mhaske, A., Miani, A., Miao, H., Michaloliakos, I., Michel, C., Middleton, H., Milano, L., Miller, A. L., Millhouse, M., Mills, J. C., Milotti, E., Milovich-Goff, M. C., Minazzoli, O., Minenkov, Y., Mishkin, A., Mishra, C., Mistry, T., Mitra, S., Mitrofanov, V. P., Mitselmakher, G., Mittleman, R., Mo, G., Mogushi, K., Mohapatra, S. R. P., Mohite, S. R., Molina-Ruiz, M., Mondin, M., Montani, M., Moore, C. J., Moraru, D., Morawski, F., Moreno, G., Morisaki, S., Mours, B., Mow-Lowry, C. M., Mozzon, S., Muciaccia, F., Mukherjee, Arunava, Mukherjee, D., Mukherjee, S., Mukherjee, Subroto, Mukund, N., Mullavey, A., Munch, J., Muñiz, E. A., Murray, P. G., Nagar, A., Nardecchia, I., Naticchioni, L., Nayak, R. K., Neil, B. F., Neilson, J., Nelemans, G., Nelson, T. J. N., Nery, M., Neunzert, A., Ng, K. Y., Ng, S., Nguyen, C., Nguyen, P., Nichols, D., Nichols, S. A., Nissanke, S., Nocera, F., Noh, M., North, C., Nothard, D., Nuttall, L. K., Oberling, J., O’Brien, B. D., Oganesyan, G., Ogin, G. H., Oh, J. J., Oh, S. H., Ohme, F., Ohta, H., Okada, M. A., Oliver, M., Olivetto, C., Oppermann, P., Oram, Richard J., O’Reilly, B., Ormiston, R. G., Ortega, L. F., O’Shaughnessy, R., Ossokine, S., Osthelder, C., Ottaway, D. J., Overmier, H., Owen, B. J., Pace, A. E., Pagano, G., Page, M. A., Pagliaroli, G., Pai, A., Pai, S. A., Palamos, J. R., Palashov, O., Palomba, C., Pan, H., Panda, P. K., Pang, P. T. H., Pankow, C., Pannarale, F., Pant, B. C., Paoletti, F., Paoli, A., Parida, A., Parker, W., Pascucci, D., Pasqualetti, A., Passaquieti, R., Passuello, D., Patricelli, B., Payne, E., Pearlstone, B. L., Pechsiri, T. C., Pedersen, A. J., Pedraza, M., Pele, A., Penn, S., Perego, A., Perez, C. J., Périgois, C., Perreca, A., Perriès, S., Petermann, J., Pfeiffer, H. P., Phelps, M., Phukon, K. S., Piccinni, O. J., Pichot, M., Piendibene, M., Piergiovanni, F., Pierro, V., Pillant, G., Pinard, L., Pinto, I. M., Piotrzkowski, K., Pirello, M., Pitkin, M., Plastino, W., Poggiani, R., Pong, D. Y. T., Ponrathnam, S., Popolizio, P., Porter, E. K., Powell, J., Prajapati, A. K., Prasai, K., Prasanna, R., Pratten, G., Prestegard, T., Principe, M., Prodi, G. A., Prokhorov, L., Punturo, M., Puppo, P., Pürrer, M., Qi, H., Quetschke, V., Quinonez, P. J., Raab, F. J., Raaijmakers, G., Radkins, H., Radulesco, N., Raffai, P., Rafferty, H., Raja, S., Rajan, C., Rajbhandari, B., Rakhmanov, M., Ramirez, K. E., Ramos-Buades, A., Rana, Javed, Rao, K., Rapagnani, P., Raymond, V., Razzano, M., Read, J., Regimbau, T., Rei, L., Reid, S., Reitze, D. H., Rettegno, P., Ricci, F., Richardson, C. J., Richardson, J. W., Ricker, P. M., Riemenschneider, G., Riles, K., Rizzo, M., Robertson, N. A., Robinet, F., Rocchi, A., Rodriguez-Soto, R. D., Rolland, L., Rollins, J. G., Roma, V. J., Romanelli, M., Romano, R., Romel, C. L., Romero-Shaw, I. M., Romie, J. H., Rose, C. A., Rose, D., Rose, K., Rosińska, D., Rosofsky, S. G., Ross, M. P., Rowan, S., Rowlinson, S. J., Roy, P. K., Roy, Santosh, Roy, Soumen, Ruggi, P., Rutins, G., Ryan, K., Sachdev, S., Sadecki, T., Sakellariadou, M., Salafia, O. S., Salconi, L., Saleem, M., Samajdar, A., Sanchez, E. J., Sanchez, L. E., Sanchis-Gual, N., Sanders, J. R., Santiago, K. A., Santos, E., Sarin, N., Sassolas, B., Sathyaprakash, B. S., Sauter, O., Savage, R. L., Savant, V., Sawant, D., Sayah, S., Schaetzl, D., Schale, P., Scheel, M., Scheuer, J., Schmidt, P., Schnabel, R., Schofield, R. M. S., Schönbeck, A., Schreiber, E., Schulte, B. W., Schutz, B. F., Schwarm, O., Schwartz, E., Scott, J., Scott, S. M., Seidel, E., Sellers, D., Sengupta, A. S., Sennett, N., Sentenac, D., Sequino, V., Sergeev, A., Setyawati, Y., Shaddock, D. A., Shaffer, T., Shahriar, M. S., Sharma, A., Sharma, P., Shawhan, P., Shen, H., Shikauchi, M., Shink, R., Shoemaker, D. H., Shoemaker, D. M., Shukla, K., Shyamsundar, S., Siellez, K., Sieniawska, M., Sigg, D., Singer, L. P., Singh, D., Singh, N., Singha, A., Singhal, A., Sintes, A. M., Sipala, V., Skliris, V., Slagmolen, B. J. J., Slaven-Blair, T. J., Smetana, J., Smith, J. R., Smith, R. J. E., Somala, S., Son, E. J., Soni, S., Sorazu, B., Sordini, V., Sorrentino, F., Souradeep, T., Sowell, E., Spencer, A. P., Spera, M., Srivastava, A. K., Srivastava, V., Staats, K., Stachie, C., Standke, M., Steer, D. A., Steinke, M., Steinlechner, J., Steinlechner, S., Steinmeyer, D., Stocks, D., Stops, D. J., Stover, M., Strain, K. A., Stratta, G., Strunk, A., Sturani, R., Stuver, A. L., Sudhagar, S., Sudhir, V., Summerscales, T. Z., Sun, L., Sunil, S., Sur, A., Suresh, J., Sutton, P. J., Swinkels, B. L., Szczepańczyk, M. J., Tacca, M., Tait, S. C., Talbot, C., Tanasijczuk, A. J., Tanner, D. B., Tao, D., Tápai, M., Tapia, A., Martin, E. N. Tapia San, Tasson, J. D., Taylor, R., Tenorio, R., Terkowski, L., Thirugnanasambandam, M. P., Thomas, M., Thomas, P., Thompson, J. E., Thondapu, S. R., Thorne, K. A., Thrane, E., Tinsman, C. L., Saravanan, T. R., Tiwari, Shubhanshu, Tiwari, S., Tiwari, V., Toland, K., Tonelli, M., Tornasi, Z., Torres-Forné, A., Torrie, C. I., Tosta e Melo, I., Töyrä, D., Trail, E. A., Travasso, F., Traylor, G., Tringali, M. C., Tripathee, A., Trovato, A., Trudeau, R. J., Tsang, K. W., Tse, M., Tso, R., Tsukada, L., Tsuna, D., Tsutsui, T., Turconi, M., Ubhi, A. S., Ueno, K., Ugolini, D., Unnikrishnan, C. S., Urban, A. L., Usman, S. A., Utina, A. C., Vahlbruch, H., Vajente, G., Valdes, G., Valentini, M., Vallisneri, M., van Bakel, N., van Beuzekom, M., van den Brand, J. F. J., Van Den Broeck, C., Vander-Hyde, D. C., van der Schaaf, L., Van Heijningen, J. V., van Veggel, A. A., Vardaro, M., Varma, V., Vass, S., Vasúth, M., Vecchio, A., Vedovato, G., Veitch, J., Veitch, P. J., Venkateswara, K., Venugopalan, G., Verkindt, D., Veske, D., Vetrano, F., Viceré, A., Viets, A. D., Vinciguerra, S., Vine, D. J., Vinet, J. -Y., Vitale, S., Vivanco, Francisco Hernandez, Vo, T., Vocca, H., Vorvick, C., Vyatchanin, S. P., Wade, A. R., Wade, L. E., Wade, M., Walet, R., Walker, M., Wallace, G. S., Wallace, L., Walsh, S., Wang, J. Z., Wang, S., Wang, W. H., Wang, Y. F., Ward, R. L., Warden, Z. A., Warner, J., Was, M., Watchi, J., Weaver, B., Wei, L. -W., Weinert, M., Weinstein, A. J., Weiss, R., Wellmann, F., Wen, L., Weßels, P., Westhouse, J. W., Wette, K., Whelan, J. T., Whiting, B. F., Whittle, C., Wilken, D. M., Williams, D., Williams, R. D., Williamson, A. R., Willis, J. L., Willke, B., Winkler, W., Wipf, C. C., Wittel, H., Woan, G., Woehler, J., Wofford, J. K., Wong, C., Wright, J. L., Wu, D. S., Wysocki, D. M., Xiao, L., Yamamoto, H., Yang, L., Yang, Y., Yang, Z., Yap, M. J., Yazback, M., Yeeles, D. W., Yu, Hang, Yu, Haocun, Yuen, S. H. R., Zadrożny, A. K., Zadrożny, A., Zanolin, M., Zelenova, T., Zendri, J. -P., Zevin, M., Zhang, J., Zhang, L., Zhang, T., Zhao, C., Zhao, G., Zhou, M., Zhou, Z., Zhu, X. J., Zimmerman, A. B., Zucker, M. E., Zweizig, J., Centre National de la Recherche Scientifique (CNRS)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon, Université Nice Sophia Antipolis (... - 2019) (UNS), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National des Sciences Appliquées - Rennes (INSA Rennes), Institut National des Sciences Appliquées (INSA)-Université de Rennes (UNIV-RENNES)-Institut National des Sciences Appliquées (INSA)-École Nationale Supérieure des Sciences Appliquées et de Technologie (ENSSAT)-Centre National de la Recherche Scientifique (CNRS)-IMT Atlantique Bretagne-Pays de la Loire (IMT Atlantique), Institut Mines-Télécom [Paris] (IMT)-Institut Mines-Télécom [Paris] (IMT), Centre National de la Recherche Scientifique (CNRS)-École normale supérieure - Paris (ENS Paris), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Centre National de la Recherche Scientifique (CNRS)-Sorbonne Université (SU)-Collège de France (CdF (institution)), Abbott, R, Abbott, T, Abraham, S, Acernese, F, Ackley, K, Adams, C, Adhikari, R, Adya, V, Affeldt, C, Agathos, M, Agatsuma, K, Aggarwal, N, Aguiar, O, Aich, A, Aiello, L, Ain, A, Ajith, P, Allen, G, Allocca, A, Altin, P, Amato, A, Anand, S, Ananyeva, A, Anderson, S, Anderson, W, Angelova, S, Ansoldi, S, Antier, S, Appert, S, Arai, K, Araya, M, Areeda, J, Arene, M, Arnaud, N, Aronson, S, Arun, K, Ascenzi, S, Ashton, G, Aston, S, Astone, P, Aubin, F, Aufmuth, P, Aultoneal, K, Austin, C, Avendano, V, Babak, S, Bacon, P, Badaracco, F, Bader, M, Bae, S, Baer, A, Baird, J, Baldaccini, F, Ballardin, G, Ballmer, S, Bals, A, Balsamo, A, Baltus, G, Banagiri, S, Bankar, D, Bankar, R, Barayoga, J, Barbieri, C, Barish, B, Barker, D, Barkett, K, Barneo, P, Barone, F, Barr, B, Barsotti, L, Barsuglia, M, Barta, D, Bartlett, J, Bartos, I, Bassiri, R, Basti, A, Bawaj, M, Bayley, J, Bazzan, M, Becsy, B, Bejger, M, Belahcene, I, Bell, A, Beniwal, D, Benjamin, M, Bentley, J, Bergamin, F, Berger, B, Bergmann, G, Bernuzzi, S, Berry, C, Bersanetti, D, Bertolini, A, Betzwieser, J, Bhandare, R, Bhandari, A, Bidler, J, Biggs, E, Bilenko, I, Billingsley, G, Birney, R, Birnholtz, O, Biscans, S, Bischi, M, Biscoveanu, S, Bisht, A, Bissenbayeva, G, Bitossi, M, Bizouard, M, Blackburn, J, Blackman, J, Blair, C, Blair, D, Blair, R, Bobba, F, Bode, N, Boer, M, Boetzel, Y, Bogaert, G, Bondu, F, Bonilla, E, Bonnand, R, Booker, P, Boom, B, Bork, R, Boschi, V, Bose, S, Bossilkov, V, Bosveld, J, Bouffanais, Y, Bozzi, A, Bradaschia, C, Brady, P, Bramley, A, Branchesi, M, Brau, J, Breschi, M, Briant, T, Briggs, J, Brighenti, F, Brillet, A, Brinkmann, M, Brockill, P, Brooks, A, Brooks, J, Brown, D, Brunett, S, Bruno, G, Bruntz, R, Buikema, A, Bulik, T, Bulten, H, Buonanno, A, Buskulic, D, Byer, R, Cabero, M, Cadonati, L, Cagnoli, G, Cahillane, C, Bustillo, J, Callaghan, J, Callister, T, Calloni, E, Camp, J, Canepa, M, Cannon, K, Cao, H, Cao, J, Carapella, G, Carbognani, F, Caride, S, Carney, M, Carullo, G, Diaz, J, Casentini, C, Castaneda, J, Caudill, S, Cavaglia, M, Cavalier, F, Cavalieri, R, Cella, G, Cerda-Duran, P, Cesarini, E, Chaibi, O, Chakravarti, K, Chan, C, Chan, M, Chao, S, Charlton, P, Chase, E, Chassande-Mottin, E, Chatterjee, D, Chaturvedi, M, Chen, H, Chen, X, Chen, Y, Cheng, H, Cheong, C, Chia, H, Chiadini, F, Chierici, R, Chincarini, A, Chiummo, A, Cho, G, Cho, H, Cho, M, Christensen, N, Chu, Q, Chua, S, Chung, K, Chung, S, Ciani, G, Ciecielag, P, Cieslar, M, Ciobanu, A, Ciolfi, R, Cipriano, F, Cirone, A, Clara, F, Clark, J, Clearwater, P, Clesse, S, Cleva, F, Coccia, E, Cohadon, P, Cohen, D, Colleoni, M, Collette, C, Collins, C, Colpi, M, Constancio, M, Conti, L, Cooper, S, Corban, P, Corbitt, T, Cordero-Carrion, I, Corezzi, S, Corley, K, Cornish, N, Corre, D, Corsi, A, Cortese, S, Costa, C, Cotesta, R, Coughlin, M, Coughlin, S, Coulon, J, Countryman, S, Couvares, P, Covas, P, Coward, D, Cowart, M, Coyne, D, Coyne, R, Creighton, J, Creighton, T, Cripe, J, Croquette, M, Crowder, S, Cudell, J, Cullen, T, Cumming, A, Cummings, R, Cunningham, L, Cuoco, E, Curylo, M, Canton, T, Dalya, G, Dana, A, Daneshgaran-Bajastani, L, D'Angelo, B, Danilishin, S, D'Antonio, S, Danzmann, K, Darsow-Fromm, C, Dasgupta, A, Datrier, L, Dattilo, V, Dave, I, Davier, M, Davies, G, Davis, D, Daw, E, Debra, D, Deenadayalan, M, Degallaix, J, De Laurentis, M, Deleglise, S, Delfavero, M, De Lillo, N, Del Pozzo, W, Demarchi, L, D'Emilio, V, Demos, N, Dent, T, De Pietri, R, De Rosa, R, De Rossi, C, Desalvo, R, de Varona, O, Dhurandhar, S, Diaz, M, Diaz-Ortiz, M, Dietrich, T, Di Fiore, L, Di Fronzo, C, Di Giorgio, C, Di Giovanni, F, Di Giovanni, M, Di Girolamo, T, Di Lieto, A, Ding, B, Di Pace, S, Di Palma, I, Di Renzo, F, Divakarla, A, Dmitriev, A, Doctor, Z, Donovan, F, Dooley, K, Doravari, S, Dorrington, I, Downes, T, Drago, M, Driggers, J, Du, Z, Ducoin, J, Dupej, P, Durante, O, D'Urso, D, Dwyer, S, Easter, P, Eddolls, G, Edelman, B, Edo, T, Edy, O, Effler, A, Ehrens, P, Eichholz, J, Eikenberry, S, Eisenmann, M, Eisenstein, R, Ejlli, A, Errico, L, Essick, R, Estelles, H, Estevez, D, Etienne, Z, Etzel, T, Evans, M, Evans, T, Ewing, B, Fafone, V, Fairhurst, S, Fan, X, Farinon, S, Farr, B, Farr, W, Fauchon-Jones, E, Favata, M, Fays, M, Fazio, M, Feicht, J, Fejer, M, Feng, F, Fenyvesi, E, Ferguson, D, Fernandez-Galiana, A, Ferrante, I, Ferreira, E, Ferreira, T, Fidecaro, F, Fiori, I, Fiorucci, D, Fishbach, M, Fisher, R, Fittipaldi, R, Fitz-Axen, M, Fiumara, V, Flaminio, R, Floden, E, Flynn, E, Fong, H, Font, J, Forsyth, P, Fournier, J, Frasca, S, Frasconi, F, Frei, Z, Freise, A, Frey, R, Frey, V, Fritschel, P, Frolov, V, Fronze, G, Fulda, P, Fyffe, M, Gabbard, H, Gadre, B, Gaebel, S, Gair, J, Galaudage, S, Ganapathy, D, Gaonkar, S, Garcia-Quiros, C, Garufi, F, Gateley, B, Gaudio, S, Gayathri, V, Gemme, G, Genin, E, Gennai, A, George, D, George, J, Gergely, L, Ghonge, S, Ghosh, A, Ghosh, S, Giacomazzo, B, Giaime, J, Giardina, K, Gibson, D, Gier, C, Gill, K, Glanzer, J, Gniesmer, J, Godwin, P, Goetz, E, Goetz, R, Gohlke, N, Goncharov, B, Gonzalez, G, Gopakumar, A, Gossan, S, Gosselin, M, Gouaty, R, Grace, B, Grado, A, Granata, M, Grant, A, Gras, S, Grassia, P, Gray, C, Gray, R, Greco, G, Green, A, Green, R, Gretarsson, E, Griggs, H, Grignani, G, Grimaldi, A, Grimm, S, Grote, H, Grunewald, S, Gruning, P, Guidi, G, Guimaraes, A, Guixe, G, Gulati, H, Guo, Y, Gupta, A, Gupta, P, Gustafson, E, Gustafson, R, Haegel, L, Halim, O, Hall, E, Hamilton, E, Hammond, G, Haney, M, Hanke, M, Hanks, J, Hanna, C, Hannam, M, Hannuksela, O, Hansen, T, Hanson, J, Harder, T, Hardwick, T, Haris, K, Harms, J, Harry, G, Harry, I, Hasskew, R, Haster, C, Haughian, K, Hayes, F, Healy, J, Heidmann, A, Heintze, M, Heinze, J, Heitmann, H, Hellman, F, Hello, P, Hemming, G, Hendry, M, Heng, I, Hennes, E, Hennig, J, Heurs, M, Hild, S, Hinderer, T, Hoback, S, Hochheim, S, Hofgard, E, Hofman, D, Holgado, A, Holland, N, Holt, K, Holz, D, Hopkins, P, Horst, C, Hough, J, Howell, E, Hoy, C, Huang, Y, Hubner, M, Huerta, E, Huet, D, Hughey, B, Hui, V, Husa, S, Huttner, S, Huxford, R, Huynh-Dinh, T, Idzkowski, B, Iess, A, Inchauspe, H, Ingram, C, Intini, G, Isac, J, Isi, M, Iyer, B, Jacqmin, T, Jadhav, S, James, A, Jani, K, Janthalur, N, Jaranowski, P, Jariwala, D, Jaume, R, Jenkins, A, Jiang, J, Johns, G, Jones, A, Jones, D, Jones, J, Jones, P, Jones, R, Jonker, R, Ju, L, Junker, J, Kalaghatgi, C, Kalogera, V, Kamai, B, Kandhasamy, S, Kang, G, Kanner, J, Kapadia, S, Karki, S, Kashyap, R, Kasprzack, M, Kastaun, W, Katsanevas, S, Katsavounidis, E, Katzman, W, Kaufer, S, Kawabe, K, Kefelian, F, Keitel, D, Keivani, A, Kennedy, R, Key, J, Khadka, S, Khalili, F, Khan, I, Khan, S, Khan, Z, Khazanov, E, Khetan, N, Khursheed, M, Kijbunchoo, N, Kim, C, Kim, G, Kim, J, Kim, K, Kim, W, Kim, Y, Kimball, C, King, P, Kinley-Hanlon, M, Kirchhoff, R, Kissel, J, Kleybolte, L, Klimenko, S, Knowles, T, Koch, P, Koehlenbeck, S, Koekoek, G, Koley, S, Kondrashov, V, Kontos, A, Koper, N, Korobko, M, Korth, W, Kovalam, M, Kozak, D, Kringel, V, Krishnendu, N, Krolak, A, Krupinski, N, Kuehn, G, Kumar, A, Kumar, P, Kumar, R, Kumar, S, Kuo, L, Kutynia, A, Lackey, B, Laghi, D, Lalande, E, Lam, T, Lamberts, A, Landry, M, Lane, B, Lang, R, Lange, J, Lantz, B, Lanza, R, La Rosa, I, Lartaux-Vollard, A, Lasky, P, Laxen, M, Lazzarini, A, Lazzaro, C, Leaci, P, Leavey, S, Lecoeuche, Y, Lee, C, Lee, H, Lee, J, Lee, K, Lehmann, J, Leroy, N, Letendre, N, Levin, Y, Li, A, Li, J, Li, K, Li, T, Li, X, Linde, F, Linker, S, Linley, J, Littenberg, T, Liu, J, Liu, X, Llorens-Monteagudo, M, Lo, R, Lockwood, A, London, L, Longo, A, Lorenzini, M, Loriette, V, Lormand, M, Losurdo, G, Lough, J, Lousto, C, Lovelace, G, Luck, H, Lumaca, D, Lundgren, A, Ma, Y, Macas, R, Macfoy, S, Macinnis, M, Macleod, D, Macmillan, I, Macquet, A, Hernandez, I, Magana-Sandoval, F, Magee, R, Majorana, E, Maksimovic, I, Malik, A, Man, N, Mandic, V, Mangano, V, Mansell, G, Manske, M, Mantovani, M, Mapelli, M, Marchesoni, F, Marion, F, Marka, S, Marka, Z, Markakis, C, Markosyan, A, Markowitz, A, Maros, E, Marquina, A, Marsat, S, Martelli, F, Martin, I, Martin, R, Martinez, V, Martynov, D, Masalehdan, H, Mason, K, Massera, E, Masserot, A, Massinger, T, Masso-Reid, M, Mastrogiovanni, S, Matas, A, Matichard, F, Mavalvala, N, Maynard, E, Mccann, J, Mccarthy, R, Mcclelland, D, Mccormick, S, Mcculler, L, Mcguire, S, Mcisaac, C, Mciver, J, Mcmanus, D, Mcrae, T, Mcwilliams, S, Meacher, D, Meadors, G, Mehmet, M, Mehta, A, Villa, E, Melatos, A, Mendell, G, Mercer, R, Mereni, L, Merfeld, K, Merilh, E, Merritt, J, Merzougui, M, Meshkov, S, Messenger, C, Messick, C, Metzdorff, R, Meyers, P, Meylahn, F, Mhaske, A, Miani, A, Miao, H, Michaloliakos, I, Michel, C, Middleton, H, Milano, L, Miller, A, Millhouse, M, Mills, J, Milotti, E, Milovich-Goff, M, Minazzoli, O, Minenkov, Y, Mishkin, A, Mishra, C, Mistry, T, Mitra, S, Mitrofanov, V, Mitselmakher, G, Mittleman, R, Mo, G, Mogushi, K, Mohapatra, S, Mohite, S, Molina-Ruiz, M, Mondin, M, Montani, M, Moore, C, Moraru, D, Morawski, F, Moreno, G, Morisaki, S, Mours, B, Mow-Lowry, C, Mozzon, S, Muciaccia, F, Mukherjee, A, Mukherjee, D, Mukherjee, S, Mukund, N, Mullavey, A, Munch, J, Muniz, E, Murray, P, Nagar, A, Nardecchia, I, Naticchioni, L, Nayak, R, Neil, B, Neilson, J, Nelemans, G, Nelson, T, Nery, M, Neunzert, A, Ng, K, Ng, S, Nguyen, C, Nguyen, P, Nichols, D, Nichols, S, Nissanke, S, Nocera, F, Noh, M, North, C, Nothard, D, Nuttall, L, Oberling, J, O'Brien, B, Oganesyan, G, Ogin, G, Oh, J, Oh, S, Ohme, F, Ohta, H, Okada, M, Oliver, M, Olivetto, C, Oppermann, P, Oram, R, O'Reilly, B, Ormiston, R, Ortega, L, O'Shaughnessy, R, Ossokine, S, Osthelder, C, Ottaway, D, Overmier, H, Owen, B, Pace, A, Pagano, G, Page, M, Pagliaroli, G, Pai, A, Pai, S, Palamos, J, Palashov, O, Palomba, C, Pan, H, Panda, P, Pang, P, Pankow, C, Pannarale, F, Pant, B, Paoletti, F, Paoli, A, Parida, A, Parker, W, Pascucci, D, Pasqualetti, A, Passaquieti, R, Passuello, D, Patricelli, B, Payne, E, Pearlstone, B, Pechsiri, T, Pedersen, A, Pedraza, M, Pele, A, Penn, S, Perego, A, Perez, C, Perigois, C, Perreca, A, Perries, S, Petermann, J, Pfeiffer, H, Phelps, M, Phukon, K, Piccinni, O, Pichot, M, Piendibene, M, Piergiovanni, F, Pierro, V, Pillant, G, Pinard, L, Pinto, I, Piotrzkowski, K, Pirello, M, Pitkin, M, Plastino, W, Poggiani, R, Pong, D, Ponrathnam, S, Popolizio, P, Porter, E, Powell, J, Prajapati, A, Prasai, K, Prasanna, R, Pratten, G, Prestegard, T, Principe, M, Prodi, G, Prokhorov, L, Punturo, M, Puppo, P, Purrer, M, Qi, H, Quetschke, V, Quinonez, P, Raab, F, Raaijmakers, G, Radkins, H, Radulesco, N, Raffai, P, Rafferty, H, Raja, S, Rajan, C, Rajbhandari, B, Rakhmanov, M, Ramirez, K, Ramos-Buades, A, Rana, J, Rao, K, Rapagnani, P, Raymond, V, Razzano, M, Read, J, Regimbau, T, Rei, L, Reid, S, Reitze, D, Rettegno, P, Ricci, F, Richardson, C, Richardson, J, Ricker, P, Riemenschneider, G, Riles, K, Rizzo, M, Robertson, N, Robinet, F, Rocchi, A, Rodriguez-Soto, R, Rolland, L, Rollins, J, Roma, V, Romanelli, M, Romano, R, Romel, C, Romero-Shaw, I, Romie, J, Rose, C, Rose, D, Rose, K, Rosinska, D, Rosofsky, S, Ross, M, Rowan, S, Rowlinson, S, Roy, P, Roy, S, Ruggi, P, Rutins, G, Ryan, K, Sachdev, S, Sadecki, T, Sakellariadou, M, Salafia, O, Salconi, L, Saleem, M, Samajdar, A, Sanchez, E, Sanchez, L, Sanchis-Gual, N, Sanders, J, Santiago, K, Santos, E, Sarin, N, Sassolas, B, Sathyaprakash, B, Sauter, O, Savage, R, Savant, V, Sawant, D, Sayah, S, Schaetzl, D, Schale, P, Scheel, M, Scheuer, J, Schmidt, P, Schnabel, R, Schofield, R, Schonbeck, A, Schreiber, E, Schulte, B, Schutz, B, Schwarm, O, Schwartz, E, Scott, J, Scott, S, Seidel, E, Sellers, D, Sengupta, A, Sennett, N, Sentenac, D, Sequino, V, Sergeev, A, Setyawati, Y, Shaddock, D, Shaffer, T, Shahriar, M, Sharma, A, Sharma, P, Shawhan, P, Shen, H, Shikauchi, M, Shink, R, Shoemaker, D, Shukla, K, Shyamsundar, S, Siellez, K, Sieniawska, M, Sigg, D, Singer, L, Singh, D, Singh, N, Singha, A, Singhal, A, Sintes, A, Sipala, V, Skliris, V, Slagmolen, B, Slaven-Blair, T, Smetana, J, Smith, J, Smith, R, Somala, S, Son, E, Soni, S, Sorazu, B, Sordini, V, Sorrentino, F, Souradeep, T, Sowell, E, Spencer, A, Spera, M, Srivastava, A, Srivastava, V, Staats, K, Stachie, C, Standke, M, Steer, D, Steinke, M, Steinlechner, J, Steinlechner, S, Steinmeyer, D, Stocks, D, Stops, D, Stover, M, Strain, K, Stratta, G, Strunk, A, Sturani, R, Stuver, A, Sudhagar, S, Sudhir, V, Summerscales, T, Sun, L, Sunil, S, Sur, A, Suresh, J, Sutton, P, Swinkels, B, Szczepanczyk, M, Tacca, M, Tait, S, Talbot, C, Tanasijczuk, A, Tanner, D, Tao, D, Tapai, M, Tapia, A, Martin, E, Tasson, J, Taylor, R, Tenorio, R, Terkowski, L, Thirugnanasambandam, M, Thomas, M, Thomas, P, Thompson, J, Thondapu, S, Thorne, K, Thrane, E, Tinsman, C, Saravanan, T, Tiwari, S, Tiwari, V, Toland, K, Tonelli, M, Tornasi, Z, Torres-Forne, A, Torrie, C, Tosta e Melo, I, Toyra, D, Trail, E, Travasso, F, Traylor, G, Tringali, M, Tripathee, A, Trovato, A, Trudeau, R, Tsang, K, Tse, M, Tso, R, Tsukada, L, Tsuna, D, Tsutsui, T, Turconi, M, Ubhi, A, Ueno, K, Ugolini, D, Unnikrishnan, C, Urban, A, Usman, S, Utina, A, Vahlbruch, H, Vajente, G, Valdes, G, Valentini, M, Vallisneri, M, van Bakel, N, van Beuzekom, M, van den Brand, J, Van Den Broeck, C, Vander-Hyde, D, van der Schaaf, L, Van Heijningen, J, van Veggel, A, Vardaro, M, Varma, V, Vass, S, Vasuth, M, Vecchio, A, Vedovato, G, Veitch, J, Veitch, P, Venkateswara, K, Venugopalan, G, Verkindt, D, Veske, D, Vetrano, F, Vicere, A, Viets, A, Vinciguerra, S, Vine, D, Vinet, J, Vitale, S, Vivanco, F, Vo, T, Vocca, H, Vorvick, C, Vyatchanin, S, Wade, A, Wade, L, Wade, M, Walet, R, Walker, M, Wallace, G, Wallace, L, Walsh, S, Wang, J, Wang, S, Wang, W, Wang, Y, Ward, R, Warden, Z, Warner, J, Was, M, Watchi, J, Weaver, B, Wei, L, Weinert, M, Weinstein, A, Weiss, R, Wellmann, F, Wen, L, Wessels, P, Westhouse, J, Wette, K, Whelan, J, Whiting, B, Whittle, C, Wilken, D, Williams, D, Williams, R, Williamson, A, Willis, J, Willke, B, Winkler, W, Wipf, C, Wittel, H, Woan, G, Woehler, J, Wofford, J, Wong, C, Wright, J, Wu, D, Wysocki, D, Xiao, L, Yamamoto, H, Yang, L, Yang, Y, Yang, Z, Yap, M, Yazback, M, Yeeles, D, Yu, H, Yuen, S, Zadrozny, A, Zanolin, M, Zelenova, T, Zendri, J, Zevin, M, Zhang, J, Zhang, L, Zhang, T, Zhao, C, Zhao, G, Zhou, M, Zhou, Z, Zhu, X, Zimmerman, A, Zucker, M, Zweizig, J, IoP (FNWI), Faculty of Science, Gravitation and Astroparticle Physics Amsterdam, Other Research IHEF (IoP, FNWI), Astroparticle Physics (IHEF, IoP, FNWI), Université Côte d'Azur (UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Université Côte d'Azur (UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Institut national des sciences de l'Univers (INSU - CNRS)-Université Nice Sophia Antipolis (... - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA), Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Université de Strasbourg (UNISTRA)-Centre National de la Recherche Scientifique (CNRS), The LIGO Scientific Collaboration, The Virgo Collaboration, Arene, M., Becsy, B., Bustillo, J. C., Diaz, J. C., Castaneda, J., Cavaglia, M., Cerda-Duran, P., Cieslar, M., Cordero-Carrion, I., Canton, T. D., Dalya, G., D'Angelo, B., D'Antonio, S., Deleglise, S., D'Emilio, V., Diaz, M. C., D'Urso, D., Fronze, G., Garcia-Quiros, C., Ghosh, A., Gonzalez, G., Guixe, G., Hubner, M. T., Isac, J. -M., Kefelian, F., Kim, C., Krolak, A., Kumar, R., Luck, H., Hernandez, I. M., Magana-Sandoval, F., Marka, S., Marka, Z., Villa, E. M., Mukherjee, A., Muniz, E. A., O'Brien, B. D., Oram, R. J., O'Reilly, B., O'Shaughnessy, R., Perigois, C., Perries, S., Pinto, I., Purrer, M., Rana, J., Rosinska, D., Roy, S., Schonbeck, A., Szczepanczyk, M. J., Tapai, M., Martin, E. N. T. S., Torres-Forne, A., Toyra, D., Vasuth, M., Vicere, A., Vivanco, F. H., Wessels, P., Yu, H., Zadrozny, A. K., and Zadrozny, A.

Subjects
Technology, Gravitational Waves, Open Data, O1, O2, LIGO, Virgo, Astronomy, Strain measurement, Gravitational Wave, open data, Data representation and management, Gravitational Waves, GWOSC, Scientific databases, gravitational waves, 01 natural sciences, General Relativity and Quantum Cosmology, Software, Documentation, DESIGN, Open Data, Computer software, Data products, LIGO, QC, 12-AXIS VIBRATION ISOLATION, media_common, Settore FIS/01, 0303 health sciences, Gravitational effects, BINARY MERGERS, Computer Science Applications, Open data, [PHYS.GRQC]Physics [physics]/General Relativity and Quantum Cosmology [gr-qc], Open science, Astrophysics - Instrumentation and Methods for Astrophysics, data analysis method, gr-qc, media_common.quotation_subject, Real-time computing, FOS: Physical sciences, O2, PUBLIC ADVANCED LIGO, General Relativity and Quantum Cosmology (gr-qc), Gravity waves, programming, O1, 03 medical and health sciences, QA76.75-76.765, Dewey Decimal Classification::000 | Allgemeines, Wissenschaft::000 | Informatik, Wissen, Systeme::004 | Informatik, SDG 17 - Partnerships for the Goals, GWOSC, Scientific databases, Data representation and management, Gravitational Waves, 0103 physical sciences, [PHYS.PHYS.PHYS-INS-DET]Physics [physics]/Physics [physics]/Instrumentation and Detectors [physics.ins-det], 010306 general physics, GRAVITATIONAL-WAVE CATALOG, Instrumentation and Methods for Astrophysics (astro-ph.IM), STFC, Astrophysique, 030304 developmental biology, Science & Technology, business.industry, Gravitational wave, Virgo, gravitational radiation, RCUK, Strain data, Data-quality information, Computer Science, Software Engineering, gravitational radiation detector, detector: sensitivity, Scientific database, monitoring, VIRGO, Sky, gravitational radiation: emission, Computer Science, ddc:004, business, astro-ph.IM
Abstract

Abbot, Rich, et al. (Virgo and MAGIC Collaboration), Advanced LIGO and Advanced Virgo are monitoring the sky and collecting gravitational-wave strain data with sufficient sensitivity to detect signals routinely. In this paper we describe the data recorded by these instruments during their first and second observing runs. The main data products are gravitational-wave strain time series sampled at 16384 Hz. The datasets that include this strain measurement can be freely accessed through the Gravitational Wave Open Science Center at http://gw-openscience.org, together with data-quality information essential for the analysis of LIGO and Virgo data, documentation, tutorials, and supporting software., The authors gratefully acknowledge the support of the United States National Science Foundation (NSF) for the construction and operation of the LIGO Laboratory and Advanced LIGO as well as the Science and Technology Facilities Council (STFC) of the United Kingdom, the Max-Planck-Society (MPS), and the State of Niedersachsen/Germany for support of the construction of Advanced LIGO and construction and operation of the GEO600 detector. Additional support for Advanced LIGO was provided by the Australian Research Council. The authors gratefully acknowledge the Italian Istituto Nazionale di Fisica Nucleare (INFN), the French Centre National de la Recherche Scientifique (CNRS) and the Foundation for Fundamental Research on Matter supported by the Netherlands Organisation for Scientific Research, for the construction and operation of the Virgo detector and the creation and support of the EGO consortium. The authors also gratefully acknowledge research support from these agencies as well as by the Council of Scientific and Industrial Research of India, the Department of Science and Technology, India, the Science & Engineering Research Board (SERB), India, the Ministry of Human Resource Development, India, the Spanish Agencia Estatal de Investigación, the Vicepresidència i Conselleria d’Innovació, Recerca i Turisme and the Conselleria d’Educació i Universitat del Govern de les Illes Balears, the Conselleria d’Educació, Investigació, Cultura i Esport de la Generalitat Valenciana, the National Science Centre of Poland, the Swiss National Science Foundation (SNSF), the Russian Foundation for Basic Research, the Russian Science Foundation, the European Commission, the European Regional Development Funds (ERDF), the Royal Society, the Scottish Funding Council, the Scottish Universities Physics Alliance, the Hungarian Scientific Research Fund (OTKA), the Lyon Institute of Origins (LIO), the Paris Île-de-France Region, the National Research, Development and Innovation Office Hungary (NKFIH), the National Research Foundation of Korea, Industry Canada and the Province of Ontario through the Ministry of Economic Development and Innovation, the Natural Science and Engineering Research Council Canada, the Canadian Institute for Advanced Research, the Brazilian Ministry of Science, Technology, Innovations, and Communications, the International Center for Theoretical Physics South American Institute for Fundamental Research (ICTP-SAIFR), the Research Grants Council of Hong Kong, the National Natural Science Foundation of China (NSFC), the Leverhulme Trust, the Research Corporation, the Ministry of Science and Technology (MOST), Taiwan and the Kavli Foundation. The authors gratefully acknowledge the support of the NSF, STFC, INFN and CNRS for provision of computational resources.

Published
2021

46. Risk Management and Insurance Grads Hit the Ground Running: Classroom lessons, internships and support organizations help new insurance employees to be productive from the first day on the job

Author

Ewing, Lance

Subjects
Risk management, Internship programs, Company business management, Risk management, Business, Insurance
Abstract

One morning, a mother went into her son's room. 'Wake up, son. It's time to go to school!' she said. The son replied, 'But Mom, I don't want to go [...]

Published
2022

47. Constant Monitoring + AI = Rx for Personal Health: An audacious Chinese entrepreneur wants to test your body for everything. But are computers really smart enough to make sense of all that data?

Author

Duncan, David Ewing

Subjects
Medical innovations -- Forecasts and trends, Precision medicine -- Technology application -- Innovations, Artificial intelligence -- Forecasts and trends, Physiologic monitoring -- Technology application -- Innovations, Biological markers -- Innovations -- Technology application, Market trend/market analysis, Artificial intelligence, Technology application, Business, Computers and office automation industries, High technology industry
Abstract

'This smart mirror isn't very smart,' says Jun Wang, standing in front of a full-length mirror wearing designer jeans ripped at the knees. 'It's just a camera and a mirror,' [...]

Published
2017

48. Treatment of infants with ureteropelvic junction obstruction: findings from the PURSUIT network

Author

Jordon C. King, Elizabeth Juarez-Colunga, Gemma Beltran, Nicolette K. Janzen, Parker Adams, George Chiang, Vijaya M. Vemulakonda, Carter Sevick, Emily Ewing, Allison Kempe, and Alison W. Saville

Subjects
Nephrology, Pyeloplasty, medicine.medical_specialty, Pediatrics, Urology, medicine.medical_treatment, 030232 urology & nephrology, Ureteropelvic junction, Hydronephrosis, 030204 cardiovascular system & hematology, Article, 03 medical and health sciences, 0302 clinical medicine, Initial visit, Electronic health record, Internal medicine, medicine, Humans, Kidney Pelvis, In patient, business.industry, Infant, medicine.disease, Prenatal Hydronephrosis, Treatment Outcome, medicine.anatomical_structure, Urologic Surgical Procedures, business, Ureteral Obstruction
Abstract

PURPOSE: Studies based on administrative databases show that infant pyeloplasty is associated with minority race/ethnicity but lack clinical data that may influence treatment. Our objective was to identify clinical and demographic factors associated with pyeloplasty in infants from three large tertiary centers. METHODS: We reviewed infants with unilateral Society for Fetal Urology (SFU) grade 3-4 hydronephrosis seen at three tertiary centers from 2/1/2018-9/30/2019. Patients were excluded if > 6 months old or treated surgically prior to the initial visit. Outcomes were: pyeloplasty < age 1 year and SFU grade on most recent ultrasound (US) within the first year. Covariables included: age at the initial visit, race/ethnicity, treating site, insurance type, febrile UTI, and initial imaging findings. Univariable and multivariable analyses were performed using log-rank tests and Cox proportional hazards models, respectively. RESULTS: 197 patients met study criteria; 19.3% underwent pyeloplasty. Pyeloplasty was associated with: treating site (p=0.03), SFU 4 on initial US (p =0.001), MAG-3 (p 20 minutes (p < 0.001) in patients undergoing a MAG-3 (n=107). MAG-3 (p

Published
2021

49. Horizons and Group Motivational Enhancement Therapy: HIV Prevention for Alcohol-Using Young Black Women, a Randomized Experiment

Author

Jessica M. Sales, Ariadna Capasso, Ralph J. DiClemente, James W. Hardin, Gina M. Wingood, Sarah W. Feldstein Ewing, Erin L. P. Bradley, Stephen G. West, Tiffaney L. Renfro, Teaniese L. Davis, Jennifer L. Brown, Angela D. Bryan, Yu Liu, Janet E. Rosenbaum, and Eve Rose

Subjects
Georgia, Epidemiology, Sexual Behavior, media_common.quotation_subject, Gonorrhea, Sexually Transmitted Diseases, Psychological intervention, HIV Infections, law.invention, Condoms, 03 medical and health sciences, symbols.namesake, 0302 clinical medicine, Condom, law, 030225 pediatrics, medicine, Humans, 030212 general & internal medicine, Poisson regression, media_common, Chlamydia, business.industry, Random assignment, Public Health, Environmental and Occupational Health, Motivational enhancement therapy, Abstinence, medicine.disease, Black or African American, Alcoholism, symbols, Female, business, Demography
Abstract

Introduction Black women are at disproportionately greater risk for HIV and sexually transmitted infections than women of other ethnic/racial backgrounds. Alcohol use may further elevate the risk of HIV/sexually transmitted infection acquisition and transmission. Study Design A random-assignment parallel-group comparative treatment efficacy trial was conducted with random assignment to 1 of 3 conditions. Setting/participants The sample comprised 560 Black or African American women aged 18–24 years who reported recent unprotected vaginal or anal sex and recent alcohol use. Participants were recruited from community settings in Atlanta, Georgia, from January 2012 to February 2014. Intervention A Group Motivational Enhancement Therapy module was designed to complement a Centers for Disease Control and Prevention–designated evidence-based intervention (Horizons) to reduce sexual risk behaviors, alcohol use, and sexually transmitted infections, with 3 comparison groups: (1) Horizons + Group Motivational Enhancement Therapy intervention, (2) Horizons + General Health Promotion intervention, and (3) enhanced standard of care. Main outcome measures Outcome measures included safe sex (abstinence or 100% condom use); condom nonuse; proportion of condom use during sexual episodes; incident chlamydia, gonorrhea, and trichomonas infections; and problematic alcohol use measured by Alcohol Use Disorders Identification Test score. Treatment effects were estimated using an intention-to-treat protocol‒generalized estimating equations with logistic regression for binomial outcomes and Poisson regression for count outcomes. Analyses were conducted between October 2018 and October 2019. Results Participants assigned to Horizons + Group Motivational Enhancement Therapy had greater odds of safe sex (AOR=1.45, 95% CI=1.04, 2.02, p=0.03), greater proportion of condom use (AOR=1.68, 95% CI=1.18, 2.41, p=0.004), and lower odds of condom nonuse (AOR=0.57, 95% CI=0.38, 0.83, p=0.004). Both interventions had lower odds of problematic alcohol use (Horizons: AOR=0.57, 95% CI=0.39, 0.85, p=0.006; Horizons + Group Motivational Enhancement Therapy: AOR=0.61, 95% CI=0.41, 0.90, p=0.01). Conclusions Complementing an evidence-based HIV prevention intervention with Group Motivational Enhancement Therapy may increase safer sexual behaviors and concomitantly reduce alcohol use among young Black women who consume alcohol. Trial registration This study is registered at www.clinicaltrials.gov NCT01553682.

Published
2021

50. Effect of dexmedetomidine on sevoflurane-induced neurodegeneration in neonatal rats

Author

Andreas W. Loepke, Samuel Y. Lee, Jeong-Rim Lee, Bingqing Zhang, Steve C. Danzer, Brian A. Upton, Rylon D. Hofacer, Bernadin Joseph, and Loren Ewing

Subjects
Apoptosis, Hippocampal formation, Neuroprotection, Sevoflurane, Heart rate, Animals, Hypnotics and Sedatives, Medicine, Rats, Wistar, Dexmedetomidine, General anaesthetic, Oxygen saturation (medicine), Cell Death, Dose-Response Relationship, Drug, business.industry, Neurotoxicity, Brain, medicine.disease, Rats, Neuroprotective Agents, Anesthesiology and Pain Medicine, Animals, Newborn, Anesthesia, Anesthetics, Inhalation, Neurotoxicity Syndromes, business, medicine.drug
Abstract

Background Structural brain abnormalities in newborn animals after prolonged exposure to all routinely used general anaesthetics have raised substantial concerns for similar effects occurring in millions of children undergoing surgeries annually. Combining a general anaesthetic with non-injurious sedatives may provide a safer anaesthetic technique. We tested dexmedetomidine as a mitigating therapy in a sevoflurane dose-sparing approach. Methods Neonatal rats were randomised to 6 h of sevoflurane 2.5%, sevoflurane 1% with or without three injections of dexmedetomidine every 2 h (resulting in 2.5, 5, 10, 25, 37.5, or 50 μg kg−1 h−1), or fasting in room air. Heart rate, oxygen saturation, level of hypnosis, and response to pain were measured during exposure. Neuronal cell death was quantified histologically after exposure. Results Sevoflurane at 2.5% was more injurious than at 1% in the hippocampal cornu ammonis (CA)1 and CA2/3 subfields; ventral posterior and lateral dorsal thalamic nuclei; prefrontal, retrosplenial, and somatosensory cortices; and subiculum. Although sevoflurane 1% did not provide complete anaesthesia, supplementation with dexmedetomidine dose dependently increased depth of anaesthesia and diminished responses to pain. The combination of sevoflurane 1% and dexmedetomidine did not reliably reduce neuronal apoptosis relative to an equianaesthetic dose of sevoflurane 2.5%. Conclusions A sub-anaesthetic dose of sevoflurane combined with dexmedetomidine achieved a level of anaesthesia comparable with that of sevoflurane 2.5%. Similar levels of anaesthesia caused comparable programmed cell death in several developing brain regions. Depth of anaesthesia may be an important factor when comparing the neurotoxic effects of different anaesthetic regimens.

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results